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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Malaria är en av vår tids viktigaste sjukdomar ur ett globalt perspektiv. Årligen dör över en halv 
miljon människor i malaria, framförallt drabbas gravida kvinnor och barn under fem år. Över 90 
% av dödsfallen sker i Afrika söder om Sahara. Ökad motståndskraft hos malariaparasiten mot 
nya artemisinin-baserade kombinationsterapier (ACT) hotar de globala framgångar som nyligen 
skett i kampen mot malaria. 
Ett omfattande malariakontrollprogram introducerades på Zanzibar 2003, vilket är ett 
pionjärprojekt i Afrika avseende hur effektivt enkla kontrollmetoder kan reducera 
parasitförekomsten i ett geografiskt avgränsat område; så som massdistribution av impregnerade 
myggnät, gratis tillgång till effektiva ACT läkemedel, införandet av snabbtester för förbättrad 
diagnostik (Rapid Diagnostic Tests, RDT) och sprejning inomhus med insekticider. Zanzibar har 
genom sitt effektiva kontrollprogram uppnått ett stadium av pre-elimination och står nu inför 
utmaningen att utrota malaria. För att uppnå detta mål krävs nya verktyg och strategier för 
förbättrad identifiering av malariafall och noggrann övervakning av läkemedelsresistens. 
I denna avhandling studerades tillämpningen av mycket känsliga molekylära metoder för att 
säkerställa optimal övervakning och potentiell begränsning av malariatransmissionen, och hur 
dessa verktyg kan bidra till att uppnå målsättningen att utrota malaria på Zanzibar.  
I Studie I studerades selektionen av resistensmarkörer hos feberpatienter efter introduktionen av 
ACT i form av artesunat-amodiakin (ASAQ) på Zanzibar år 2003. Fyra väletablerade mutationer i 
två gener associerade med läkemedelsresistens analyserades: ”Plasmodium falciparum 
chloroquine resistance transporter” (pfcrt) position K76T samt ”P. falciparum multidrug 
resistance 1” (pfmdr1) positioner N86Y, Y184F och D1246Y. Efter sju års användning av ASAQ 
sågs ingen selektion av mutationer associerade med resistens mot amodiakin. 
I Studie II utvärderades tre extraktionsmetoder för att utvinna DNA från använda snabbtester. 
Möjligheten att utvinna parasit-DNA från snabbtester utgör en intressant möjlighet till förbättrad 
molekylärepidemiologisk övervakning. DNA-extraktion från prover insamlade i Zanzibar visade 
att parasit-DNA kan bevaras på snabbtester under fältmässiga förhållanden i Afrika. 
I Studie III utvecklades och utvärderades en ny mycket känslig metod (cytb-qPCR) för detektion 
av lågdensitets parasitemier i små mängder blod som har bevarats på filter paper. Denna metod 
användes i Studie IV för påvisande av malariainfektion hos individer som deltagit i 
tvärsnittsstudier som utfördes år 2005-2013 på Zanzibar. Lågdensitets parasitemier i 
lågtransmissionsmiljöer utgör en viktig reservoar för fortsatt malaria transmission. Dessa 
infektioner undgår upptäckt då de ligger under detektionsnivåerna för både RDT och mikroskopi 
(ca. 100 parasiter/μl blod) vilket, i tillägg till att de ofta är asymptomatiska (dvs ej ger upphov till 
feber), gör att de undgår läkemedelsbehandling. Vi påvisade en kvarvarade parasitreservoar som 
bestod av P. falciparum och P. malaria och som fanns främst hos individer i 5-25 års ålder. 
Parasitemierna var låga, men det fanns en hög diversitet i parasitpopulationen. Vi såg ingen 
selektion av mutationer associerade med resistens mot amodiakin, men prevalensen av vissa 
mutationer var betydligt högre bland asymptomatiska än symptomatiska infektioner. 
I Studie V rapporterades resultat från den hittills största fältstudien där loop-mediated isothermal 
amplification (LAMP), en högkänslig, fältanpassad molekylär diagnostisk metod använts för att 
påvisa förekomst av malariainfektion. Totalt analyserades prover från 3983 asymtomatiska 
individer med LAMP vid två laboratorier på Zanzibar. LAMP detekterade 3.4 gånger fler 
malariainfekterade individer än RDT. Under studiens gång uppstod DNA-kontaminering av 
proverna som krävde upprepad rengöring av all LAMP utrustning och reagenser. Studien visar att 
LAMP är ett enkelt och känsligt molekylärt verktyg för användning i fält, men att ett slutet hög-
kapacitets system skulle vara optimalt för att reducera risken för kontaminering. 
Sammanfattningsvis visar avhandlingen att konventionella metoders möjlighet att identifiera 
individer med malariainfektion inte är tillräckligt hög för att utrota malaria på Zanzibar. För att nå 
detta mål krävs nya molekylära metoder för förbättrad identifiering och bekämpning av den 
kvarvarande parasitpopulationen. Detta är extra betydelsefullt i en tid då både läkemedelsresistens 
hos malariaparasiten och resistens mot bekämpningsmedel hos myggorna hotar de globala 
framstegen inom malariakontroll. Den snabba övergången från hög till låg malariatransmission på 
Zanzibar under de senaste åtta åren utgör en unik forskningsmöjlighet för att studera hur 
molekylära metoder kan bidra för att uppnå malariaeliminering i en pre-eliminations miljö. I 
denna avhandling har tillämpningen av molekylära metoder för förbättrad malariaövervakning 
och kontroll på Zanzibar studerats, och resultaten bidrar därmed till ökad förståelse för 
användbarheten av dessa verktyg i Afrika söder om Sahara. 
 
  
ABSTRACT 
Increased funding combined with effective malaria control methods for prevention, diagnosis, 
and treatment, has resulted in a 30% reduction of the global malaria burden over the last 
decade. As malaria prevalence declines in areas of successful malaria control, the proportion 
of subpatent infections that fall below the detection level of malaria rapid diagnostic tests 
(RDTs) and microscopy increases. In these areas new tools and strategies are required for 
detecting and targeting residual parasite populations. Furthermore, there is an emerging 
resistance to the artemisinin-based combination therapies (ACTs), which is the recommended 
first-line treatment for uncomplicated Plasmodium falciparum malaria. This resistance is a 
serious threat to the recent achievements in the reduction of the global malaria burden.  
The aim of this thesis was to gain insight into the application of modern molecular methods 
for enhanced malaria infection detection and surveillance of antimalarial drug resistance in a 
pre-elimination setting such as Zanzibar. 
Study I assessed whether seven years of wide scale use of artesunate-amodiaquine (ASAQ) 
as first-line treatment selected for P. falciparum single nucleotide polymorphisms (SNPs) 
associated with resistance to the ACT partner drug amodiaquine. No selection of SNPs 
associated with amodiaquine resistance was observed, indicating sustained efficacy of ASAQ 
as first-line treatment in Zanzibar.  
In Study II different methods of DNA extraction from used RDTs were evaluated and it was 
assessed whether RDTs could preserve Plasmodium DNA for the purpose of molecular 
epidemiological investigations. The Chelex-100 method proved the most sensitive method of 
DNA extraction in both RDT and filter paper samples. RDTs collected in Zanzibar provided 
parasite DNA of equal quality as filter papers, suggesting that RDTs are a valuable alternative 
for DNA storage under field conditions. 
In Study III a highly sensitive SYBR Green qPCR-RFLP assay was developed for 
Plasmodium detection and species determination in samples collected on filter paper. This 
method was applied in Study IV for characterising asymptomatic Plasmodium infections. A 
declining, albeit persistent, reservoir of parasites present at low-densities was found in 
asymptomatic individuals, highlighting the need for sensitive molecular methods in malaria 
pre-elimination settings. The study revealed important characteristics of the remaining 
parasite populations, including intriguing trends in SNPs associated with antimalarial drug 
resistance that require further investigation in order to be fully understood. 
Study V reports the hitherto largest implementation of a new molecular diagnostic tool based 
on loop-mediated isothermal amplification (LAMP), for scaled up, centralised mass-
screening of asymptomatic malaria in Zanzibar. LAMP detected 3.4 times more Plasmodium 
positive samples than RDT, and was found to be a simple and sensitive molecular tool with 
potential for use in active malaria surveillance. Contamination is, however, a concern. A 
higher throughput, affordable closed system would be ideal to avoid DNA contamination 
when processing larger numbers of samples. 
In summary, molecular methods are required for enhanced malaria infection detection and 
surveillance of antimalarial drug resistance in malaria pre-elimination settings such as 
Zanzibar. The application of molecular methods may be of particular interest for malaria 
control/elimination programs, for monitoring progress towards malaria elimination and for 
optimal orientation of program activities.  
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1 INTRODUCTION 
 
1.1 THE GLOBAL MALARIA BURDEN 
Approximately 3.2 billion people worldwide are at risk of being infected with malaria and 
developing disease. The World Health Organization (WHO) estimated 198 million cases of 
malaria and 584 000 deaths globally in 2013 [1], although some suggest that malaria 
mortality is underestimated [2]. The malaria burden is heaviest in sub-Saharan Africa where 
90% of the malaria deaths occur. Pregnant women and children under the age of five, who 
account for 78% of all deaths, are most susceptible. In 2013, an estimated 437 000 African 
children died before their fifth birthday due to malaria [1]. 
Increased funding combined with effective malaria control methods for prevention, diagnosis 
and treatment has resulted in a 30% reduction in the global malaria incidence and a 47% 
decrease in the global malaria mortality between 2000 and 2013 [1]. Out of the 97 countries 
with ongoing malaria transmission, 64 countries have reversed the incidence of malaria and 
55 are on track to meet the World Health Assembly and Roll Back Malaria Partnership target 
of reducing incidence by 75% by 2015 [1]; the long term goal being global malaria 
eradication. 
Despite these tremendous achievements many malaria endemic countries are still far from 
reaching universal coverage with life-saving malaria interventions [1]. Insecticide resistance 
in malaria vectors has been observed in 49 of 63 reporting countries. Resistance to 
artemisinin-based combination therapies (ACTs), the recommended first-line treatment for 
uncomplicated malaria, has been detected in five countries in Southeast (SE) Asia. 
Furthermore, the funding provided for malaria control in 2013 (US$ 2.7 billion) reached only 
half of the estimated costs (US$ 5.1 billion) required to achieve global targets for malaria 
control and elimination [1, 3]. The Global Malaria Eradication Programme launched in 1955 
was first to attempt malaria eradication, but funding collapsed in 1969 resulting in 
devastating resurgence of malaria in many countries [4]. This reminds us that sustained and 
sufficient financing is critical for furthering goals of global malaria eradication [5]. 
 
1.2 THE PLASMODIUM PARASITE 
The etiological agents of malaria are single celled apicomplexan parasites of the genus 
Plasmodium. There are over 250 species of Plasmodium, of which five infect humans: P. 
falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi [6]. P. falciparum is responsible 
for the majority of deaths due to malaria. It is the predominant species in sub-Saharan Africa 
and also occurs in SE Asia. P. vivax is predominant in South America and also occurs in SE 
Asia. P. malaria may occur in all malarious areas but at a low prevalence [7]. P. ovale is 
principally widespread in tropical Africa; two distinct sub species of P. ovale have recently 
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been described, P. ovale curtisi and P. ovale wallikeri [8]. P. knowlesi causes malaria in long-
tailed macaques in parts of SE Asia but has also been shown to infect humans [6]. Much of 
this thesis focuses on P. falciparum malaria due to its severity and predominance in sub-
Saharan Africa. 
The Plasmodium genome encodes approximately 5,300 genes carried on 14 chromosomes. 
The genome is highly (A + T)-rich, the overall (A + T) composition is 80.6% and rises to 
~90% in introns and intergenic regions [9]. Around 60 genes involved in antigenic variation 
(var genes) are located in the subtelomeric regions of the chromosomes [10]. 
 
1.2.1 The Plasmodium life cycle 
The lifecycle of Plasmodium species that infect humans is complex and involves a human 
host and mosquito vector [6]. Female anopheline mosquitoes transmit malaria to humans 
when taking a blood meal (Figure 1A). Motile sporozoites, which reside in the mosquito 
salivary glands, are injected into the skin of the host together with the mosquito saliva. The 
average inoculum measured under laboratory conditions contained 125 sporozoites (range 0-
1300), although inoculum in the field are likely to contain less than 100 sporozoites per bite 
[11]. 
After deposition in the skin (usually in the dermis) the motile sporozoites must locate and 
penetrate blood vessels in order to reach the second destination, the liver, where the 
sporozoites invade hepatocytes (Figure 1B). The process from deposition to hepatocyte 
invasion is thought to take 2-3 hours. Inside the hepatocytes each sporozoite multiplies 
producing 10 000-30 000 daughter merozoites during 5.5-8 days [6]. Finally the hepatocyte 
schizonts burst, liberating merozoites that then invade erythrocytes (red blood cells [RBCs]) 
(Figure 1C).  
Asexual replication occurs in the erythrocytes. The parasites go through several stages, 
starting as early (ring stage) trophozoites, developing into mature trophozoites, and finally 
becoming schizonts which rupture the RBC releasing daughter merozoites. Each burst RBC 
releases between 6 and 30 merozoites, which then infect new RBCs within 30-90 seconds 
[12]. Symptoms of malaria are associated with this stage of the life cycle, usually referred to 
as the asexual or blood-stage cycle. Symptoms usually start approximately 6-8 days after 
emerging from the liver [6]. 
Some blood-stage parasites develop into longer lived sexual forms known as gametocytes. 
The sexual forms are taken up by a feeding anopheline mosquito (Figure 1D), where sexual 
reproduction takes place. A male and female gametocyte forms an ookinete, which develops 
into an oocyst in the mosquito mid-gut. The oocyst bursts liberating sporozoites that migrate 
to the salivary glands of the mosquito [6]. It takes 10-21 days development in the mosquito 
before sporozoites can be injected into a new host during a blood meal. 
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The Plasmodium life cycle is similar between species, with some distinguishing differences. 
For example, some P. vivax and P. ovale parasites remain dormant in the liver as 
hypnozoites, causing relapse of malaria between two weeks to more than one year after the 
initial infection. The cycle of asexual replication in the RBCs takes roughly 48 hours for P. 
falciparum, P. vivax and P. ovale, 72 hours for P. malariae and only 24 hours for P. knowlesi 
[6]. And finally in P. falciparum the gametocytemia is delayed, peaking 7-10 days after the 
initial peak in asexual stage parasite densities [13]. 
 
 
Figure 1: The lifecycle of Plasmodium in the human body and the anopheline mosquito. 
The estimated numbers of parasites for each life cycle stage are shown in boxes. Reprinted 
from The Lancet, 2013, White NJ et al., Malaria, with permission from Elsevier. 
 
1.3 THE HUMAN HOST 
1.3.1 Immunity 
Individuals residing in malaria endemic regions eventually develop resistance to malaria 
through repeated exposure. Children born in malaria endemic areas, with moderate 
transmission intensity, acquire protection against severe malaria by the age of five [6]. Older 
children and young adults develop complete protection against illness with malaria and are 
eventually considered partially immune. This immunity protects the host against illness with 
malaria but does not eliminate the infection. These individuals harbour asymptomatic malaria 
infections without any signs of disease (Figure 2). 
Immunity to malaria is considered to be non-sterile, complex, and not well understood. 
Immunity develops relatively slowly and is said to wane quickly when adults leave malaria 
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endemic regions, suggesting that frequent exposure to malaria is needed to maintain 
immunity [14]. Studies have shown that protective immunity against sporozoite-induced 
infection requires antigen-specific CD8
+
 T cells, which inhibit development of liver-stage 
parasites. T-cells are primed early in the lymph nodes draining the skin where some 
sporozoites are deposited. Dendritic cells in the skin or in lymph nodes are important in the 
priming of the Plasmodium specific CD8
+
 T cells [11]. It is usually assumed that humoral 
responses are key in blood-stage immunity, where B-cells produce antibodies that block the 
merozoite invasion of erythrocytes [14]. It is thought that pro-inflammatory cytokines such as 
interferon-γ and tumor necrosis factor play essential roles in protective immunity against 
blood-stage Plasmodium infections, but are also involved in immunopathology of severe 
malaria [14, 15]. Antigenic variation in the parasites and short lived nature of malaria 
immunity in the human host has hampered the development of a malaria vaccine. 
 
Figure 2: Relation between age and malaria severity in an area of endemic 
transmission. Reprinted by permission from Macmillan Publishers Ltd: Nature Immunology, 9: 
725-732, © 2008. 
 
1.3.2 Human genetics 
The genus Plasmodium is estimated to have evolved ~150 million years ago, long before the 
existence of Homo sapiens [16]. Humans have evolved in the presence of malaria, and the 
coevolution has helped shape the human genome [17]. There are a number of polymorphisms 
that are thought to be protective against severe forms of malaria. The global distributions of 
sickle cell disease, thalassemias, Glucose-6-phosphate dehydrogenase (G6PD) deficiency and 
blood group polymorphisms mirrors that of malaria, suggesting that malaria has been a 
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selective force for these mutations [12, 16]. Additionally, genetic variations in human P450 
genes (e.g. CYP2C8, CYP3A4 and CYP2A6) result in differential metabolism of antimalarial 
drugs in humans (i.e. pharmacogenetics) and have important implications in both antimalarial 
drug effectiveness and tolerability [18, 19]. 
1.3.2.1 G6PD deficiency 
G6PD is a key enzyme in the pentose phosphate pathway and is important in RBCs for 
protecting against oxidative stress [20]. G6PD deficiency, an X-linked recessive hereditary 
disease characterised by abnormally low levels of G6PD, is common in many malaria 
endemic regions [13]. Over 140 mutations lead to different enzyme activity levels 
predisposing to haemolysis in response to certain triggers such as food, illness or medication. 
G6PD deficiency has been proposed to modulate disease severity or to be protective against 
malaria [21]. G6PD deficiency is also important in the choice of antimalarial treatment. 
Primaquine is used to treat P. vivax and P. ovale hypnozoites as well as P. falciparum 
gametocytes. However, primaquine causes oxidative stress in the RBC, and people with 
G6PD deficiency risk having adverse reactions such as severe haemolysis, severe haemolytic 
anaemia and potentially death if exposed to certain primaquine doses [22]. 
 
1.4 THE MOSQUITO VECTOR 
Malaria is transmitted through the bites of female Anopheles mosquitoes. There are over 500 
recognised species of Anopheles, 70 of which are able to transmit malaria to the human host 
and 40 of which are responsible for the majority of malaria transmission worldwide [7]. 
Anopheles mosquitoes breed in still standing water; the dominant vector species are 
anthropophilic with a preference for human feeding, have longer lifespan, and elevated 
vectorial capacity. The Anopheles gambiae complex, prevalent in sub-Saharan Africa, is the 
most efficient malaria vector. It contains four principal species: An. gambiae sensu stricto, 
An. arabiensis, An. merus and An. melas. Three other highly anthropophilic vectors in sub-
Saharan Africa are An. funestus, An. moucheti and An. nili [7].  
Environmental factors such as climate, seasonality, rainfall patterns, temperature and 
presence of vegetation and surface water play an important role in vector distribution and 
malaria transmission [7]. Adult female Anopheles can live up to one month, but are estimated 
only to survive 1-2 weeks in nature. The development of the malaria parasite in the mosquito 
slows as temperatures decline. P. falciparum transmission becomes much less likely when 
temperatures fall below 18ºC and parasites cease development completely at temperatures 
below 16ºC [23], explaining why malaria caused by P. falciparum is mainly confined to the 
tropics [24]. 
Insecticides such as pyrethroids are a corner stone in malaria vector control. Widespread 
deployment of pyrethroids in agriculture and vector control has resulted in the emergence of 
resistance in mosquitoes. Mechanisms for resistance include changes in the insecticide target 
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site that reduces binding (knock down resistance) and increases in the rate of insecticide 
metabolism lowering the amount of insecticide reaching the target site (e.g. over expression 
of P450 genes) [25]. Resistance may also be cuticular, whereby modifications in the insect 
cuticle and/or digestive tract lining reduce the uptake of insecticides, or behavioural whereby 
modifications in the insect behaviour help avoid contact with insecticides [25]. An. gambiae 
sensu stricto and An. funestus are typically indoor resting (endophilic) and feed at night when 
most humans are asleep. These species are therefore susceptible to currently employed vector 
control methods such as indoor residual spraying (IRS) and insecticide treated nets (ITNs). 
The effectiveness of these control methods can be reduced by mosquito behavioural changes, 
such as natural or insecticide-induced avoidance of contact with surfaces, feeding upon 
humans when they are active and unprotected outdoors, feeding upon animals (many vectors 
are zoophagic) and outdoor resting. Such changes may arise by altered taxonomic 
composition of the vector population or altered expression of innately flexible behaviours in 
the mosquito. An. arabiensis is an example of a species that enters a house but then rapidly 
exits again, even if it has not taken a successful blood meal. An. arabiensis has therefore 
some pre-existing behavioural resilience and is often responsible for persisting residual 
transmission following successful scale up of ITNs and IRS in sub-Saharan Africa [26]. 
 
1.5 MALARIA ENDEMICITY AND TRANSMISSION 
Malaria burden is difficult to estimate, especially in low income countries where data 
collection and reporting quality is poor. The lack of a population denominator makes the real 
incidence of malaria difficult to assess [7]. Malaria endemicity is a complex indicator of 
disease prevalence. It is dependent on host exposure, parasite and vector characteristics, 
environmental factors, and may also fluctuate seasonally. There are several measures of 
endemicity, for example prevalence of enlarged spleen (spleen rate [SR]), proportion of 
population with laboratory confirmed malaria infection (parasite rate [PR]), number of 
infective bites per person per year (entomological inoculation rate [EIR]) and number of 
microscopically confirmed malaria cases detected during one year per unit population (annual 
parasite incidence [API]) [7]. Malaria endemicity can be categorised into four groups 
depending on SR or PR: 
 Hypo-endemic areas where prevalences are <11% 
 Meso-endemic areas where prevalences are between 11 and 50% 
 Hyper-endemic areas where prevalences are between 51 and 75% 
 Holo-endemic areas where prevalences are >75% 
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Malaria endemicity can further be classified into stable and unstable transmission, depending 
on the average number of feeds that a mosquito takes on a human being during its life [27]. 
Entomologic parameters are a direct measure of infection rates, but obtaining accurate data is 
technically complex, highly time consuming, and expensive due to the difficulties of 
obtaining entomological-based matrices, especially in areas of low transmission. There are 
also ethical considerations of exposing human beings to malaria infection and measurement 
error issues [7]. These limitations also apply for the related EIR, which is used to estimate 
malaria transmission and calculated as the product of the vector biting rate times the 
proportion of mosquitoes infected with sporozoite-stage malaria parasites. EIRs in sub-
Saharan Africa are highly variable ranging from <1 to >1000 infective bites per person per 
year. It is considered that substantial reductions in malaria prevalence are likely to be 
achieved when EIRs are reduced to levels of <1 infective bite [28]. In the 2014 World 
malaria report the WHO classified transmission based on API as high (stable) transmission 
where >1 case occurred per 1000 population and low (unstable) transmissions where 0-1 
cases occurred per 1000 population (Figure 3). 
 
 
Figure 3: Global malaria endemic situation based on API. Reprinted from WHO world 
malaria report 2014 [1]. 
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1.5.1 Serology for measuring transmission  
An alternative method for measuring transmission involves the serological detection of 
infection histories [29]. This has several marked advantages over entomological and 
parasitological parameters, especially in areas of low transmission. PR and EIR are 
considered insufficiently sensitive to accurately report endemicity and transmission when PR 
and EIRs have been reduced to <1% or <1 infective bite per person per year. As antibodies 
can persist for months or years after infection it is possible to avoid seasonal variation in 
transmission, and age-specific seroprevalence rates reflect long-term exposure trends [30]. 
Seroprevalence of IgG antibodies, detected by indirect ELISA, to three recombinant blood-
stage malaria antigens (MSP-119, MSP-2 and AMA-1) correlate with medium and long term 
trends in malaria transmission [31]. Serological assays allow surveillance of transmission 
where levels are approaching elimination and sero-conversion rates can provide estimates of 
recent changes in malaria transmission intensity [32]. 
 
1.6 CLINICAL FEATURES OF SYMPTOMATIC MALARIA 
Malaria is an acute febrile illness. Symptoms usually appear 10-15 days after an infective 
mosquito bite. Clinical malaria is classified into uncomplicated (generally non-lethal) and 
severe (life-threatening) malaria. 
 
1.6.1 Uncomplicated malaria 
Symptoms of uncomplicated malaria are non-specific and difficult to distinguish from other 
typical viral or bacterial infections. Symptoms include fever, headache, fatigue, muscle aches, 
abdominal discomfort, nausea and vomiting. Cases of uncomplicated malaria may also have 
mild anaemia and a palpable spleen after a few days. The liver can become enlarged in small 
children, and mild jaundice may occur in adults. Symptoms are classically associated with 
irregular fever peaks that occur every 24, 48 or 72 hours depending on the malaria species, 
although this periodicity is rarely observed. Fever results from schizont rupture during the 
blood-stage cycle, releasing parasite waste products and cellular material into the blood. This 
activates monocytes and macrophages and induces the release of proinflammatory cytokines 
[6]. If uncomplicated malaria is not treated it can quickly develop into severe malaria and 
result in a fatal outcome. 
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1.6.2 Severe malaria 
Severe malaria is usually caused by P. falciparum. The manifestations are dependent on age, 
and primarily occur in non-immunes and small children. Clinical features of severe malaria 
may include: 
 Hyper parasitaemia (>2% infected RBC) 
 Cerebral malaria with seizures or coma 
 Metabolic acidosis 
 Acute respiratory distress  
 Severe anaemia (Haemoglobin <5g/100 mL) 
 Hypoglycaemia (<2.2 mmol/L) 
 Pulmonary oedema 
 Acute kidney injury 
 Jaundice 
Severe anaemia and hypoglycaemia are more common in children, whereas acute pulmonary 
oedema, acute kidney injury, and jaundice are more common in adults; cerebral malaria and 
acidosis occur in all age groups [6].  
1.6.2.1 Pathogenesis of P. falciparum malaria 
P. falciparum expresses antigenically variant, strain-specific, adhesive proteins which locate 
to the membrane of the host erythrocyte. The P. falciparum erythrocyte membrane protein 1 
(PfEMP1) mediates sequestration, a process involving the attachment of the infected 
erythrocyte to endothelial surface receptors in veins and capillaries (i.e. cytoadherence). The 
process of sequestration protects P. falciparum from the clearance of infected erythrocytes by 
the spleen, but is also responsible for much of the pathology associated with severe malaria. 
Receptors such as ICAM1 in the brain, chondroitin sulphate A in the placenta, and CD36 in 
most other organs bind infected erythrocytes, which in turn bind uninfected erythrocytes (a 
process known as rosetting), resulting in microvascular obstruction and blockage of the 
microcirculatory blood flow [12]. Anaemia is thought to mainly result from increased 
destruction of infected and uninfected RBCs passing through the spleen. 
  
 10 
1.7 MALARIA DIAGNOSIS 
Early and accurate diagnosis of malaria is essential for effective disease management and 
malaria surveillance. The WHO recommends prompt parasite-based diagnosis either by 
microscopy or malaria rapid diagnostic tests (RDTs) in all patients with suspected malaria 
before treatment is administered. This policy has been adopted in the majority of countries 
with ongoing malaria transmission [1]. Diagnostic testing improves the management of all 
patients with febrile illnesses, and may also help to reduce the emergence and spread of 
antimalarial drug resistance. 
 
1.7.1 Microscopy 
Light microscopy remains the gold standard for malaria diagnosis [33]. It involves 
preparation of thin and thick blood smears, for the detection of parasites in the peripheral 
blood. Thick films are useful for detecting low-density malaria, whereas thin films provide 
more accurate data on parasite density and malaria species. Specimens are prepared prior to 
examination by staining, most commonly with Giemsa stain. Parasite densities (in 
parasites/µL) are estimated in thick blood smears by counting the number of parasites present 
against 200 white blood cells (WBC). The numbers of parasites are then multiplied by 40 to 
give the parasite count per microliter (assuming a standard value of 8000 WBC/µL). In thin 
blood smears the number of infected RBCs are counted in 10 000 RBCs (or approximately 40 
monolayer cell fields using the 100 X oil immersion objective in a standard microscope) [34]. 
Detection limits of microscopy are highly dependent on the quality of the reagents, the 
microscope, and on the experience of the microscopy reader. The expected sensitivity that 
can be achieved by an experienced microscopist in thick blood films is around 50 
parasites/µL blood or 0.001% infected RBCs (assuming a total RBC count of 5 x 10
6
/µL of 
blood) [34]. However, under field conditions the sensitivity is likely to be closer to 100 
parasites/µL, and in highly optimal conditions it may reach 5-20 parasites/µL [35]. 
Microscopy is a cheap, well established and informative method, allowing for assessment of 
species, life cycle stage and quantification of parasite densities. Microscopy is also labour 
intensive, time consuming (30-60 min) and the quality is highly dependent on the reagents, 
microscope and microscopist [35, 36]. It is not optimal for the detection of low-density 
parasitaemias and it is challenging to keep up motivation for careful microscopic examination 
when more than 95% of slides are negative for malaria. 
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1.7.2 Rapid diagnostic tests  
There are currently over 150 commercially available RDT brands whose performance is 
assessed by the WHO and the Foundation for Innovative New Diagnostics (FIND). The 
sensitivity of RDTs (~50-100 parasites/µL for P. falciparum, and 200-500 parasites/µL for 
pan-Plasmodium) is similar to that of light microscopy. Results are produced within 15-20 
minutes, requiring no additional equipment and minimal expertise [29]. However, RDTs do 
not provide parasite quantification, and are considered more expensive (0.6-2.5 US$) than 
light microscopy (0.12-0.40 US$) [36]. Malaria RDTs are lateral-flow devices which use 
antibody capture to detect soluble malaria antigens by immunochromatography. The principle 
target antigens for RDTs are P. falciparum histidine-rich protein 2 (PfHRP2), produced only 
by P. falciparum, Plasmodium and species-specific lactate dehydrogenase (LDH) and 
aldolase [35]. Figure 4 describes the RDT components and mode of action. 
 
 
 
 
 
 
 
 
Figure 4: Components and mode of action of malaria rapid diagnostic tests. Adapted 
from Cnops et al, Malaria Journal, 2011, 10:67. 
The RDT strip is usually packaged in a plastic case or cardboard folder. The buffer, sample 
and conjugate pads are mounted on the plastic backing at the proximal end of the strip. The 
blood sample (5-15µL depending on RDT brand) is added to the sample pad, after which the 
buffer provided with the kit is added to the buffer pad. The buffer mixes with the blood lysing 
the RBC. The absorption pad mounted at the distal end of the plastic strip results in 
migration, driven by capillary forces, of the mixture across the surface of a nitrocellulose 
membrane. The mixture first passes the conjugation pad where mobile monoclonal 
antibodies, against a malaria antigen target, bind malaria antigens if present in the sample. 
The antibodies are labelled (conjugated), commonly with colloidal gold particles. The 
antigen-antibody-conjugate complex migrates across the nitrocellulose membrane until it 
reaches a narrow section of immobile capture antibodies. These antibodies capture the 
antigen-antibody-conjugate creating a cherry red coloured test line. Excess antibody-
conjugate migrates further until it reaches control antibodies generating a control line. The 
absorption pad at the distal end absorbs the residual blood containing mixture [37]. 
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The performance of RDTs may vary. False negative results occur mostly at low parasite 
densities, but also sometimes at relatively high densities [38]. For PfHRP2-based RDTs 
possible explanations include deletions of the PfHRP2 gene [39-45], high levels of antigen or 
anti-PfHRP2 antibodies which block the target antigen detection (prozone effect) [38, 46], 
and varying manufacturing quality and thermal stability [29]. The HRP2 antigen persists for 
weeks in the blood after an infection is cleared resulting in false positive results; this limits 
the usefulness of PfHRP2 RDTs in high-transmission areas [33, 34, 47]. LDH based RDTs 
detect either all Plasmodium species (pLDH), or P. falciparum and P. vivax specific LDH 
(PfLDH and PvLDH). LDH does not persist in the bloodstream as does PfHRP2, but LDH-
based RDTs are less sensitive than PfHRP2-based RDTs for P. falciparum detection and 
perform less well than in areas of low parasite density [33]. Many RDT brands now combine 
pan-Plasmodium and species-specific detection in two or three line tests. 
RDTs may also serve as a source of parasite DNA. Increased deployment of RDTs in health 
care facilities and cross-sectional surveys may facilitate passive and active collection of 
biological material for molecular surveillance [37, 48-50]. 
 
1.7.3 Molecular methods 
The field of molecular biology has witnessed great advances in the development of nucleic 
acid amplification methods, which provide the, to date, most sensitive and accurate tools to 
detect and identify pathogens [51]. 
1.7.3.1 Polymerase chain reaction (PCR) 
PCR involves primer-directed amplification of a specific fragment of DNA, under set 
temperature cycling conditions using thermostable Taq polymerase. A number of nested PCR 
(nPCR) [52-57] and real-time quantitative PCR (qPCR) [58-63] methods have been 
developed for malaria detection and determination of Plasmodium species; qPCR can also be 
used to estimate parasite densities [60, 61]. The most common targets for malaria specific 
PCR are the 18S ribosomal RNA (rRNA) genes in genomic DNA, and cytochrome b (cytb) 
gene in mitochondrial DNA. The detection limit of PCR is ~0.7-5 parasite/µL [36] however, 
RNA-based detection can be even more sensitive [61, 64, 65] and can distinguish between 
asexual and sexual stages providing a more accurate detection of gametocytes [64, 66, 67]. 
PCR-based methods are now used frequently for evaluating other diagnostic tools [47, 68-
70], in clinical trials for monitoring antimalarial drug and vaccine efficacy in vivo [71, 72], 
and for estimating parasite prevalence in low transmission setting [52, 73-76]. PCR is, 
however, not yet available in resource-limited settings due to the requirement of complex 
equipment, reagents and know-how [77]; PCR is also prone to DNA contamination [78]. 
1.7.3.2 Loop-mediated isothermal amplification (LAMP) 
Isothermal amplification techniques, such as LAMP, have potential for field diagnosis of 
malaria infection [79]. LAMP employs isothermal Bst DNA polymerase with strand 
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displacement activity. LAMP can therefore be performed at a single temperature with a 
simple heating block or water bath, reducing the need for sensitive and expensive machinery 
such as PCR thermocyclers. The LAMP reaction is primed by a specific set of four to six 
primers that identify six distinct regions on the target DNA. The design of the primers result 
in DNA loop formations and several inverted repeats of the target DNA, creating cauliflower-
like structures [80]. This increases the copy number of the amplified product and reduces the 
time-to-result (30-60 min) [36, 79]. DNA amplification can be detected by the naked eye by a 
change in turbidity caused by white precipitate of magnesium pyrophosphate formed during 
the reaction, or under UV fluorescence if a fluorescent indicator such as calcein is added to 
the reagents [79]. Visual detection avoids the need for opening the reaction tube post-
amplification, hence the reaction is conducted in a closed system which reduces the risk of 
DNA contamination [51]. The Bst polymerase is less prone to inhibitors such as haemoglobin 
than Taq polymerase. LAMP can be conducted with DNA extracted by crude extraction 
methods with a sensitivity comparable to PCR (5-7 parasites/µL) [81-83]. 
LAMP methodology was first reported in 2000 by Notomi et al. [80]. Poon et al. (2006) [84] 
were first to develop a LAMP assay detecting P. falciparum 18S rRNA genes, which was 
shortly followed by a malaria species-specific LAMP published by Han et al. (2007) [82]. 
Polly et al. (2010) [81] developed a LAMP method targeting mitochondrial DNA, improving 
the sensitivity of malaria detection. In 2013 Polly et al. clinically evaluated a temperature 
stable LAMP reaction kit developed by FIND and Eiken Chemical Company, Japan. 
The Loopamp
TM
 MALARIA Pan/Pf Detection Kit (Eiken Chemical Company, Japan) is a 
field-friendly kit, comprising strips of reaction tubes containing vacuum dried and 
temperature stable reaction components for either genus (Pan)-specific or P. falciparum (Pf)-
specific malaria detection [85]. The kit has been evaluated both in laboratory and field 
settings [83, 85-88]. The kit can be used with minimal training [85], and with blood samples 
collected on filter paper [83]. Although the cost of LAMP is estimated to be a tenth of that of 
conventional PCR [84], the cost of the field friendly kit is still at 5.3 US$ per reaction [36]. 
The potential risk of contamination is reduced by using a closed system. However, the risk of 
contamination is not eliminated due to the high efficiency of the reaction [89, 90]. 
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1.8 TREATMENT OF P. FALCIPARUM MALARIA AND ANTIMALARIAL DRUG 
RESISTANCE 
Malaria is a treatable and curable disease. When treated promptly with effective antimalarial 
drugs, uncomplicated malaria has a mortality of roughly 0.1% [6]. P. falciparum malaria has 
throughout history proven its capacity to develop resistance to virtually all deployed 
antimalarial drugs. The emergence of artemisinin resistant parasite populations currently 
poses one of the largest challenges in malaria control and elimination [91-93]. 
 
1.8.1 Malaria treatment guidelines 
The WHO recommended first-line treatment for uncomplicated P. falciparum malaria is 
ACTs [94]. ACTs are composed of a fast acting artemsinsin derivative together with a more 
slowly eliminating partner drug, the combination of two drugs is thought to slow the 
development of resistance [95]. The recommended ACTs include artmether+lumefantrine 
(AL), artesunate+amodiaquine (ASAQ), artesunate+mefloquine, artesunate+sulfadoxine-
pyrimethamine and dihydroartemisinin+piperaquine. The choice of ACT should be based on 
the level of resistance to the partner drug in the region/country, and should include at least 
three days treatment with an artemisinin derivative. In order to reduce malaria transmission in 
areas targeting pre-elimination or elimination, WHO also recommends the addition of a 
single low dose of primaquine (0.25 mg/kg) for treatment of uncomplicated P. falciparum 
malaria. Severe malaria requires parenteral treatment with either artesunate or quinine [94]. 
ACTs are effective against all malaria species, although chloroquine may be used to treat P. 
vivax in areas where still effective. Treatment of P. vivax and P. ovale with either chloroquine 
or ACT should be combined with a 14-day course of primaquine to eliminate hypnozoites. 
 
1.8.2 Drug Resistance and Tolerance 
Antimalarial drug resistance is defined as “the ability of a parasite strain to survive and/or 
multiply despite the proper administration and absorption of an antimalarial drug in the dose 
normally recommended” [94]. Whilst drug resistance may lead to treatment failure, not all 
treatment failures are caused by drug resistance. Treatment failure can also be the result of 
incorrect dosing, problems of treatment adherence (compliance), poor drug quality and 
comprised drug absorption. All these factors may however, accelerate the spread of true drug 
resistance by exposure of the parasites to inadequate drug levels [94]. 
Development of resistance may be gradual or stepwise, involving a period where drug-
tolerant parasites are still killed by the therapeutic doses of the administered drug but 
withstand higher levels of the drug than fully sensitive parasites. Antimalarial drugs with 
longer half-lives persist after treatment, providing a post-prophylactic effect. Tolerant 
parasites can infect individuals after treatment, when there are still residual levels of the drug 
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that are too high to enable infection by fully sensitive parasites. This may spur development 
of drug resistance by enabling the tolerant mutation to spread in the population [96, 97]. 
 
1.8.3 Mechanisms of drug resistance 
Drug resistance generally involves a genetic event, such as introduction of single nucleotide 
polymorphisms (SNPs), gene copy number variations or microsatellites, which alters the 
parasite susceptibility to the drug. Some of the key mechanisms of resistance include: 
 Reducing or eliminating the drug-target interaction e.g. by: 
 Reduced uptake of the drug (decreased import) 
 Increased export/efflux of the drug 
 Compartmentalising the drug away from its active site 
 Metabolising the drug to an inactive form before it reaches its target 
 Non-activation of a pro-drug 
 Increased target substrate which out competes the drug at the target site 
 Alteration of the drug target e.g. by: 
 Changing the affinity of the drug to its target 
 Overproduction of the target 
 Eliminating the need of the target by inducing alternative pathways 
 Dormancy, whereby the parasite enters a quiescent, developmentally arrested state, 
and continues with the normal cell cycle progression once drug concentrations have 
waned 
 Overexpression of systems to handle indirect effects of a drug, e.g. DNA repair 
mechanisms 
 
1.8.4 Methods to assess antimalarial drug resistance 
There are several methods for assessing antimalarial drug resistance, each with inherent 
advantages and disadvantages. Different methodologies make it difficult to compare inter-
study results. The Worldwide Antimalarial Resistance Network (WWARN) was established 
to coordinate antimalarial resistance monitoring [98]. The Plasmodium Diversity Network 
Africa (PDNA) is an African initiative established across 11 countries in sub-Saharan Africa 
for the assessment of parasite diversity in malaria-endemic regions. They aim to play a key 
roal in the global effort for tracking and responding to antimalarial drug resistance [99]. 
1.8.4.1 In vivo clinical trials 
Antimalarial drug efficacy is commonly assessed by monitoring in vivo responses to the drug. 
Accurate estimation of the parasite clearance rate is critical for assessing in vivo efficacy, 
especially in artemisinin derivatives [94]. Patients are usually followed up after treatment for 
28 or 42 days. Therapeutic responses are characterised as adequate clinical and 
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parasitological response, early treatment failure and late treatment failure. Molecular 
genotyping is required to distinguish between new and recrudescent infections. Studies are 
usually done in children under the age of five to mitigate the role of immunity in high 
transmission areas. Clinical trials should optimally be conducted every two years [1], but in 
vivo assessment of therapeutic efficacy is time consuming, expensive and requires expert 
personnel. Furthermore, clinical trials become impractical in areas of low transmission, where 
it is difficult to reach a required sample size [100]. 
1.8.4.2 In vitro/ex vivo assays 
Antimalarial drug susceptibility can also be assessed by in vitro assays that measure the 
susceptibility of malaria parasites to drugs in culture [94]. Ex vivo refers to studies on fresh 
parasite isolates, whereas in vitro assays are done on parasites that have been maintained for 
more than two generations. In vitro assays usually measure the drug concentration at which 
50% of the parasite growth is inhibited (IC50) compared to the unexposed control [100]. 
Artemsinsin resistance is monitored using the ring-stage survival assay (RSA), which 
measures the proportion of viable parasites that develop into second-generation rings or 
trophozoites after a six hour pulse of dihydroartemisinin [101]. In vitro assays do not 
necessary correlate with the in vivo outcomes, where host immunity plays a large role [102]. 
1.8.4.3 Surveillance of molecular markers of drug resistance 
Molecular markers of drug resistance are a useful tool to track the spread of resistance alleles 
in patient samples. It complements the more laborious and expensive in vivo and in vitro drug 
efficacy screening. It enables drug policy makers to prepare for first-line antimalarial changes 
before in vivo treatment failures have reached critical levels. It also allows for assessment of 
resistance levels after a treatment has been withdrawn due to resistance, when it is unethical 
to conduct efficacy trials. Molecular marker may however, not predict clinical treatment 
failures but may be a sign of increasing tolerance [10]. 
 
1.8.5 Nomenclature of molecular markers 
Genes are written in italics (e.g. pfcrt), the proteins encoded by the gene in capital letters (e.g. 
PfCRT). Amino acid changes in proteins are given as the protein name followed by the amino 
acid residue and change, using the single letter amino acid code (e.g. PfCRT K76T, i.e. lysine 
substituted with threonine at the 76
th
 amino acid in the PfCRT protein). The SNPs encoding 
the amino acid changes are written as the gene followed by the amino acid residue and 
change (e.g. pfcrt K76T, i.e. the SNP in the pfcrt gene encoding the amino acid change at the 
76
th
 residue in the protein). 
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1.8.6 Historic review of antimalarial drugs and mechanisms of P. falciparum 
resistance 
Drugs have been used to treat and prevent malaria for centuries. This chapter will provide a 
historic overview of some of the most commonly employed antimalarials and how resistance 
has been achieved in P. falciparum. 
1.8.6.1 Quinolines and related compounds 
Quinine was the first antimalarial drug to become widely available. It was isolated from the 
bark of the cinchona tree in 1820 and was the drug of choice for treating malaria until World 
War II [10]. Reduced availability of the drug during the war drove the development of 
synthetic antimalarial drugs. Chloroquine was developed in the 1930s and was widely used 
during the 1960s and 1970s [103]. Resistance to chloroquine was first reported along the 
Thailand-Cambodia border in 1957 from where it spread throughout South and SE Asia 
[104]. Chloroquine resistance emerged independently in South America in 1959. Resistance 
was first reported in sub-Saharan Africa in the 1970s and was widespread across the 
continent by the 1980s [105]. The worldwide spread of chloroquine resistance had 
devastating effects on malaria mortality, and drove the development of other synthetic 
compounds to which resistance developed rapidly [103]. Other synthetic derivatives of 
quinine include amodiaquine, mefloquine, primaquine and piperaquine; lumefantrine is also 
structurally related to quinine [104]. 
1.8.6.2 Chloroquine 
Chloroquine, a 4-aminoquinoline, acts by interfering with the sequestration of toxic haem, 
which is produced when haemoglobin is digested by the intra-erythrocytic parasite to obtain 
amino acids. The parasite crystallises haem into haemozoin in its acidic digestive vacuole. 
Chloroquine (and other related drugs) binds to haem, preventing the detoxification process 
[104]. Parasite resistance is thought to be achieved by reduced accumulation of chloroquine 
in the digestive vacuole.  
The P. falciparum chloroquine resistance transporter (pfcrt), the key gene involved in 
resistance, was discovered in 2000 [106]. It is located on chromosome 7 and encodes a drug 
and metabolite transporter protein (PfCRT) located on the membrane of the digestive 
vacuole. The key mutation pfcrt K76T, confirmed by transfection studies, is found in 
association with other compensatory residue changes at positions PfCRT 72-76, where 
PfCRT 72-76 CVMNK is the sensitive haplotype and CVIET and SVMNT are most common 
resistant haplotypes [107]. The observed range of chloroquine resistance is dependent on the 
genetic background of the parasite line; pfcrt K76T increases tolerance to chloroquine so that 
recrudescence is likely to occur, but does not always lead to clinical failure [104]. A 
simplified hypothesis of how resistance arises involves the protonation of chloroquine in the 
acidic conditions of the digestive vacuole. Efflux of positively charged chloroquine (CQ
2+
) is 
limited by the charged lysine (PfCRT K76) in the sensitive strain. When lysine is replaced by 
the neutral threonine (as in PfCRT 76T) then CQ
2+ 
can exit down its concentration gradient 
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via PfCRT, removing the drug from its target site [104]. Verapamil, a calcium (Ca
2+
) channel 
blocker, is able to reverse resistance by competing with chloroquine for binding at PfCRT, 
blocking the efflux of the drug from the digestive vacuole [108]. 
The P. falciparum multidrug resistance 1 (pfmdr1) gene on chromosome 5 encodes an ATP-
binding cassette-type transporter (PfMDR1) [109]. PfMDR1 also sits on the membrane of the 
digestive vacuole and is thought to import solutes and drugs into the lumen of the digestive 
vacuole [110]. Pfmdr1 has been identified as an important secondary locus of chloroquine 
resistance. PfMDR1 N86Y modulates resistance to chloroquine, perhaps by reducing the 
transport of chloroquine into the digestive vacuole [104]. Other mutations at Pfmdr1 Y184F, 
S1034C, N1042D and D1246Y have been identified in field isolates. These mutations 
enhance the degree of chloroquine resistance, but do not seem to confer resistance per se 
[111]. 
1.8.6.3 Quinine 
The mode of action of quinine is not fully understood, but as chloroquine it accumulates in 
the parasite digestive vacuole and inhibits detoxification of haem. Resistance to quinine was 
first reported in 1910 [10]. Despite widespread use, resistance to quinine remains low 
(perhaps due to its short half-life of 8 hours) and is limited to SE Asia, Oceania and less 
frequently in South America [10]. Quinine resistance is thought to be mediated by multiple 
genes. Both pfcrt and pfmdr1 are involved in resistance; mutations at pfcrt K76T, pfmdr1 
N86Y and N1042D have shown to result in the loss of quinine transport. Focus has however, 
been on the Na+/H+ exchanger 1 (pfnhe1) gene located on chromosome 13 and expressed on 
the parasite plasma membrane. Specific patterns of microsatellite repeats at locus ms4760 in 
pfnhe1 are associated with increased quinine resistance [10, 104]. 
1.8.6.4 Amodiaquine 
Amodiaquine is metabolised in vivo to its active form desethylamodiaquine (DEAQ). It is 
closely related to chloroquine, with a similar mode of action, and there is some cross-
resistance between the two drugs [112]. SNPs in pfcrt and pfmdr1 have been associated, both 
in vitro and in vivo, with resistance to amodiaquine [113-116]. Strong resistance has been 
linked to the PfCRT 72-76 SVMNT motif prevalent in South America (the predominant 
haplotype in Africa and SE Asia is PfCRT 72-76 CVIET) [104, 117]. Selection of pfcrt 76T 
and pfmdr1 86Y alleles, as well as pfmdr1 1246Y and the pfmdr1 (a.a.86,184,1246) YYY 
haplotype has been shown in recurrent infections after treatment with ASAQ or amodiaquine 
alone [116, 118-123]. In the to-date most extensive report (a pooled analysis of individual 
patient data), none of the analysed pfcrt or pfmdr1 parasite genotypes were significant risk 
factors for recrudescent infections (treatment failures), but pfmdr1 86Y, 1246Y were selected 
in re-infections after treatment with ASAQ. Furthermore, in patients treated with ASAQ, 
parasites carrying pfmdr1 86Y, 1246Y, or pfcrt 76T appeared earlier during follow-up than 
those carrying pfmdr1 N86, D1246, or pfcrt K76, indicating that these mutations provide 
increased tolerance to ASAQ [116]. 
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1.8.6.5 Mefloquine 
Mefloquine was introduced in 1977, but resistance was reported from the Thai-Cambodian 
borders in 1982. The drug remains effective outside of SE Asia, and some regions of South 
America [10]. Resistance to mefloquine has been highly associated with increased pfmdr1 
copy number (2-5 amplifications of the gene) [115, 124]. Pfmdr1 amplifications are common 
in SE Asia and may also contribute to resistance against lumefantrine, quinine and 
artemisinins [125]. Pfmdr1 copy number variation is most often associated with Pfmdr1 N86 
in field isolates [116]. 
1.8.6.6 Lumefantrine 
Lumefantrine has shown to select pfcrt K76 and pfmdr1 N86, 184F, D1246, the pfmdr1 (a.a. 
86,184,1246) NFD haplotype, and increased pfmdr1 copy number [116, 122, 126-130]. 
Parasites with pfmdr1 NFD are able to withstand higher lumefantrine concentrations than 
those with pfmdr1 YYY [97, 116]. Lumefantrine and amodiaquine select in the opposite 
directions, suggesting that the mode of action of lumefantrine is not in the digestive vacuole 
but in the parasite cytoplasm [131]. Presence of pfmdr1 N86 and pfmdr1 copy number was 
shown to be a significant risk factor for recrudescence in patients treated with AL. No 
association was observed between the pfmdr1 184, pfmdr1 1246 and pfcrt polymorphisms 
and recrudescent infections in the recent pooled analysis of individual patient data [116].  
1.8.6.7 Antifolates 
Pyrimethamine was first used as antimalarial in the late 1940s, and resistance was reported 
shortly after [10]. Sulfadoxine and pyrimethamine were given as a combination drug 
(sulfadoxine-pyrimethamine [SP]) in the 1960s, to try to overcome resistance to 
monotherapy. Resistance to SP emerged in SE Asia and the Amazon basin in the mid-1970s, 
and in Africa in the 1990s [10]. Pyrimethamine targets dihydrofolate reductase (DHFR) 
activity involved in thymidylate synthesis. Sulfadoxine targets the dihydropteroate synthetase 
(DHPS) activity involved in de novo synthesis of essential folate coenzymes. These drugs act 
as competitive inhibitors of the natural enzyme substrates [104]. Resistance to sulfadoxine 
and pyrimethamine arises from the accumulation of mutations in pfdhps and pfdhfr 
respectively. In Africa the quintuple mutant pfdhps A437G, K540E, pfdhfr N51I, C59R and 
S108N results in highly resistant SP parasites and is a strong predictor of clinical failure 
[115]. 
1.8.6.8 Artemisinins 
Artemisinin, originally isolated from the herb Artemisia annua, has been used in Chinese 
medicine for centuries and was rediscovered by Chinese biomedical researchers in the 1970s 
[103]. Only in the 1990s did artemisinin and its derivatives such as artesunate, artemether and 
dihydroartemisinin become widely available outside of China. Artemisinins have a half-life 
of around 1-2 hours, are very fast acting, and reduce the parasite load quickly [10, 132]. 
Artemisinin resistance is suspected when an increase in parasite clearance time, defined as 
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parasites detectable on day 3 after ACT treatment, is observed in ≥10% of cases. Confirmed 
resistance is defined as treatment failure after oral artemisinin-based monotherapy with 
adequate antimalarial blood concentrations, evidenced by the persistence of parasites for 7 
days, or the presence of parasites at day 3 and recrudescence within 28/42 days [133]. To 
prevent development of resistance the WHO has recommended the use of artemisinins in 
combination with other antimalarials for treatment of uncomplicated malaria. 
Artemisinin is a sesquiterpene lactone endoperoxide. The mode of action of artemsinsin is not 
yet fully established. The endoperoxide bridge seems to be critical for its function [10] and is 
believed to produce the active compound upon interaction with reduced iron in haem 
moieties (deriving from haemoglobin digestion) [134] and free intracellular reduced iron 
[135]. The mechanism of action is thought to be either oxidative damage to parasite 
membranes or inactivation of parasite proteins by free radicals produced by the drug [10, 
136]. Early studies report the alkylation of specific proteins including transporters [104], iron 
sulphur proteins and the malaria translationally controlled tumor protein (TCTP) [137]. The 
PfATP6, a sarco/endoplasmic reticulum calcium-dependent ATPase (SERCA) orthologue 
has also been suggested as a target [138-140]. 
Several studies showed that P. falciparum employed a quiescence mechanism in vitro that 
allowed it to survive artemisinin treatment. Drug pressure induced a state of developmental 
arrest in sub-populations of ring-stage parasites, whereby a small number of parasites 
remained dormant for several days to weeks after the removal of the drug, before resuming 
normal growth [141-144]. An artemisinin resistant strain, obtained by long term in vitro 
culture of parasites in the presence of the drug, showed transcriptomic modifications 
associated with the resistance phenotype including overexpression of heat shock and 
erythrocyte surface proteins, and down expression of a cell cycle regulator and a DNA 
biosynthesis protein [141]. A recent in vivo population transcriptomics study showed that 
resistant parasites remained in a state of decelerated development at a young ring stage, while 
responses to mitigate protein damage caused by artemsinsin were upregulated [145]. 
Mutations in pfatp6, pfcrt, pfmdr1 and pfmdr1 amplification were initially found to modulate 
sensitivity to artesunate in vitro [146-149]. Cheeseman et al. (2012) identified, by cross-
population genomic comparisons, a region on chromosome 13 that was significantly 
associated with parasite clearance times [150]. Similarly, Takala-Harrison et al. (2013) 
identified the same region on chromosome 13, as well as two other regions on chromosome 
10 and 14 [151]. Ariey et al. (2014) conducted whole genome sequencing of an in vitro 
cultivated artemsinsin-resistant parasite line originating from Africa and clinical isolates from 
Cambodia. Non-synonymous mutations in the kelch propeller domain (pfkelch13), encoded 
on chromosome 13, were associated with clearance times both in vitro and in vivo [152]. The 
kelch protein is thought to mediate diverse cellular functions, including ubiquitin-regulated 
protein degradation and oxidative stress responses [153]. Ariey et al. reported that artemisinin 
tolerance in vitro was conferred by the pfkelch13 M476I mutation, prolonged parasite 
survival ex vivo was conferred by the Y493H, I543T, R539T, and C580Y mutations, and in 
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vivo parasite half-life was increased by Y493H, R539T, and the most prevalent C580Y 
mutation [152]. The involvement of these SNPs in artemsinsin resistance has been confirmed 
by genome editing studies [153, 154]. Straimer et al. (2014) showed that the level of 
resistance varied depending on the genetic background of the parasites, indicating the role of 
additional genetic factors [153]. Resistance was likely to arise on a particular genetic 
background common in SE Asia, with several background markers. These background 
markers may be compensatory, reducing fitness costs associated with pfkelch13 mutations, or 
enhance phenotypic effects of artemisinin resistance [155]. 
The first evidence of in vivo artemsinsin resistant malaria was observed in Western Cambodia 
in 2008, with reports of delayed parasite clearance times and treatment failures [91]. 
Treatment failures were confirmed in 2009 in Pailin, Western Cambodia, where median 
clearance times (84 hours) were significantly higher than clearance times (48 hours) in North-
western Thailand. Mutations in pfmdr1 and pfatp6 were absent in both studies and the slow 
parasite clearance in vivo did not correspond with reductions in conventional in vitro 
susceptibility testing [92]. A population genetics study discovered three distinct 
subpopulations of P. falciparum that were associated with clinical resistance to artemsinsin in 
the same location in Cambodia [156]. These subpopulations showed evidence of clonal 
expansion, suggesting that resistance may have arisen independently at least three times[157]. 
A longitudinal study conducted along the North-western border of Thailand showed that the 
proportion of patients with slow clearance rates (≥6.2 hours) increased from 0.6-20% from 
2001-2010, proving that resistance had emerged or spread westward from Cambodia. [158]. 
Recent studies have shown that the pfkelch13 mutations have originated independently in 
multiple locations [155, 159]. Ashly et al. (2014) showed that slow clearing infections 
(parasite clearance >5 hours) were strongly correlated with point mutations in pfkelch13, and 
were detected throughout mainland SE Asia from southern Vietnam to central Myanmar. 
Slow clearing parasites had a higher level of gametocytemia, suggesting greater potential for 
transmission. Importantly a six day course of ACT had high cure rates in western Cambodia 
[93].  
ACTs remain efficacious in sub-Saharan Africa [160-165]. Molecular surveillance has shown 
the absence of the SE Asian pfkelch13 alleles. Other pfkelch13 mutations have been reported 
[166-168], although the frequency of mutations does not seem to have increased over time 
[166]. It may however, be harder to quantify the amount of resistance in sub-Saharan Africa 
where host immunity may mask the loss of drug efficacy [169]. Borrmann et al. (2011) 
reported a small decline in parasitological response rates to ACTs in Kenya, perhaps due to 
reduced drug sensitivity or a reduction in population-level clinical immunity [170]. There 
have been a couple of reports of treatment failure with AL in returning travellers [171, 172], 
and Betson et al. (2014) reported persistent day 7 parasitaemia in chronic multi-species 
malaria infections in Ugandan children after AL treatment [173].  
Pfkelch13 has been identified as a key determinant of delayed parasitological clearance after 
artemisinin treatment in SE Asia [93, 152, 159]. So far resistance has been documented in 
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five countries in the Greater Mekong sub region (Cambodia, Laos, Myanmar, Thailand and 
Vietnam) [1]. Molecular markers in Pfkelch13 may provide the means for large scale 
surveillance of resistance in SE Asia, aiding the WHO plan for artemisinins resistance 
containment. In sub-Saharan Africa it is important to maintain surveillance of resistance to 
ACT partner drugs. Resistance to partner drugs has historically manifested before that of 
artemisinins [116], and may spur the development of resistance to artemisinin derivatives and 
to ACTs [174, 175]. Table 1 summarises the key established molecular markers in 
antimalarial resistant P. falciparum that have been discussed above. 
 
Table 1: Summary table of molecular markers of antimalarial drug resistance. 
Drug 
Gene 
Pfcrt Pfmdr1 Other 
Chloroquine 76T 
86Y, Y184, 1034C, 1042D, 
1246Y 
 
Quinine 76T 86Y, 1042D pfnhe1 ms4760 
Amodiaquine 76T. 72-76 SVMNT 86Y, Y184, 1246Y  
Mefloquine  N86, Amplification  
Lumefantrine K76 
N86, 184F, D1246, 
Amplification 
 
Sulphadoxine-
pyrimethamine 
  
Pfdhps 437G, 540E 
Pfdhr 51I, 59R, 108N 
Artemisinins K76 
N86, D1246, Amplification 
 
K13 propeller C580Y, 
M476I, Y439H , R539T, 
I543T  
 
1.8.7 Fitness cost of mutations 
Fitness describes the ability of a particular genotype to survive and reproduce in a given 
environment. Genetic polymorphisms conferring resistance are frequently accompanied by 
fitness costs. The spread of drug resistance may be limited by fitness costs, although 
compensatory mutations that increase virulence or transmission may accumulate after 
resistance has developed [176].  
Fitness costs can be measured in vitro by comparing growth rates and in competitive growth 
experiments. Mutations in pfcrt and pfmdr1 as well as increased pfmdr1 copy number have 
all been associated with fitness costs [176-178]. Parasites may benefit from carrying these 
mutations when under direct pressure, but are outcompeted by sensitive strains that lack the 
mutation when drug pressure is absent [177]. A typical example is the return of the 
chloroquine sensitive form (pfcrt K76) in areas where chloroquine use has been discontinued 
due to high levels of resistance [179-183].  
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1.9 MALARIA CONTROL AND MALARIA ELIMINATION 
The WHO uses the following terminology to refer to malaria endemic status [7]: 
 Malaria control: reducing malaria disease burden to a locally manageable level where 
it is no longer a public health problem. 
 Malaria elimination: interruption of local transmission; reduction to zero of the 
incidence of infection in a defined geographical area; continued measures to prevent 
re-establishment of transmission. 
 Malaria eradication: permanent reduction to zero of the worldwide incidence of 
infection; intervention measures are no longer needed. 
Successful malaria control has resulted in marked reductions in malaria prevalence over the 
past decade, re-inviting the possibility of malaria elimination in some areas. 
 
1.9.1 Corner stones in malaria control 
1.9.1.1 Vector control 
The coverage of vector control interventions in sub-Saharan Africa has increased 
substantially during the last 10 years [1]. ITNs and long lasting insecticide treated nets 
(LLINs) protect individuals by diverting or killing mosquitoes. LLINs have shown to reduce 
the number of malaria cases by 50% [184] and represent an important corner stone in malaria 
control. In 2013 almost half the population at risk had access to a ITN in their household, and 
in 2014 a total of 214 million nets were projected to be delivered to sub-Saharan Africa [1]. 
Replacing worn out nets is crucial for maintaining universal coverage [184].  
IRS involves the application of insecticides to the interior walls and surfaces of houses which 
serve as resting places for mosquitoes. The use of IRS has declined since 2010 due to 
withdrawal or downsizing of cumbersome spraying programmes. In sub-Saharan Africa, 7% 
of the population at risk were protected by this method of vector control [1]. Target vector 
control strategies to foci of transmission can scale up the type and intensity of interventions in 
a cost effective manner, and should be complemented with robust monitoring and evaluation 
[185]. Resistance to pyrethroids, the most frequently used insecticide accounting for 75% of 
total IRS coverage and used in all treated bed nets poses a threat to malaria control [3]. 
Environmental management including larval control with biological means (fish or bacteria) 
or insecticides might be cost effective in areas of high-density human populations, such as 
urban areas [27]. The WHO reported 38 countries using larval control to complement core 
vector control methods [1]. Ivermectin, an antihelminthic drug which can be given to both 
humans and animals, has been found to kill mosquitoes when taking a blood meal, and may 
thus also provide an interesting opportunity to reduce residual malaria transmission [186]. 
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1.9.1.2 Improved diagnostics 
The WHO recommends diagnosis either by microscopy or RDTs in all patients with 
suspected malaria before treatment is administered. RDTs are recommended by the WHO in 
areas where good quality microscopy is not available; 160 million RDTs were distributed in 
2013 which for the first time exceeded the number of distributed ACTs [1]. The scaled-up use 
of RDTs poses some challenges such as access to RDTs on the scale needed to achieve 
universal coverage, policy changes required for implementation at a community level, and 
targeted information and training required for proper adherence to test results [187]. 
Furthermore, missed diagnosis of malaria and new infections that become apparent soon after 
a consultation with a malaria negative RDT may undermine confidence in results [188]. 
1.9.1.3 Access to effective treatment 
Access to effective treatment in order to decrease morbidity and mortality and to interrupt 
transmission is another corner stone in malaria control. Access to antimalarials is dependent 
on supply demands being met, in order to avoid stock-outs. Subsidised antimalarials are 
currently available through public facilities in most malaria endemic areas, but only a 
proportion of those at risk have access to these sources. ACTs available through the private 
sector are priced according to market demands [131] and may be deemed as too expensive 
[189]. The T3: Test. Treat. Track. initiative was launched by the WHO in 2012 to urge the 
global malaria community to achieve universal coverage with diagnostic testing and 
antimalarial treatment, and to enhance case reporting in order to improve malaria surveillance 
systems [190]. It is also important to monitor the efficacy of ACTs, especially in the light of 
artemisinin resistance [191]. 
1.9.1.4 Chemoprophylaxis 
Intermittent administration of antimalarials at regular time points is used in areas of high 
transmission for preventing infection. Intermittent preventive treatment (IPT) is 
recommended for pregnant women (IPTp) and infants (IPTi) as well as in children under the 
age of five [3]. SP still plays an important role in IPT, although SP resistance decreases the 
treatment and prophylactic efficacy. There is an urgent need to identify a replacement drug 
with a long half-life, which is well tolerated and safe to administer during infancy and 
pregnancy [131]. The WHO also recommends seasonal malaria chemotherapy (SMC) with 
amodiaquine + SP for children aged 3-59 months in areas of highly seasonal malaria 
transmission [1].  
1.9.1.5 Malaria vaccines 
The complexity of the malaria parasite makes development of a vaccine very difficult, and 
despite decades of intense research efforts there is currently no commercially available 
malaria vaccine [1]. There are several vaccine candidates undergoing field trial, the most 
advanced is the RTS,S/AS01 [1]. RTS,S is a pre-erythrocyte vaccine based on P. falciparum 
circumsporozoite surface protein [192]. Vaccine recipients that received all planned doses of 
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RTS,S/AS01 showed a 46% reduction of severe malaria in children and 27% reduction in 
infants [1]. This falls short of the traditional goals of a vaccine, but might give infants and 
small children a better chance of surviving when most vulnerable [193]. The WHO decision 
regarding a policy recommendation for the use of RTS,S is expected in 2015 [1]. 
It has long been known that inoculation of P. falciparum sporozoites by mosquito bites 
induces high-level protection against human malaria [194]. Another vaccine candidate is the 
PfSPZ vaccine, composed of radiation attenuated P. falciparum sporozoites. Seder et al. 
(2013) report that five intravenous inoculations with the PfSPZ vaccine provided 100% 
efficacy in a Phase I safety trial in six individuals [195]. There are however, several 
limitations and logistical issues with this potential vaccine candidate such as producing 
irradiated sporozoites on an industrial scale, the need for multiple intravenous 
administrations, and the need for a cold chain during vaccine delivery. 
 
1.9.2 Malaria elimination 
WHO classifies countries according to their malaria programme phase as follows [1]: 
 Pre-elimination phase: Test positivity rate <5% among suspected malaria cases 
throughout the year and API <5 (i.e. fewer than 5 cases/1000 population). 
 Elimination phase: API <1; malaria is a notifiable disease with a manageable number 
of reported malaria cases nationwide (e.g. <1000 cases, local and imported). 
 Prevention of reintroduction: Recently endemic countries with zero local transmission 
for at least 3 years; case management of imported malaria and maintaining the 
capacity to detect malaria infection and manage clinical disease is required. 
 Malaria-free: Certified malaria free within last five years. 
The transition from malaria control to malaria elimination requires an already operating 
effective malaria control programme, with additional components such as surveillance and 
response systems that are able to detect and eliminate residual reservoirs of symptomatic and 
asymptomatic infection [196]. This requires enhanced laboratory support that embraces 
sensitive techniques, such as PCR, genotyping and serology. Research and cross-border 
collaborations are required within and between malaria eliminating countries. Modelling and 
predicting costs of achieving malaria elimination and preventing re-introduction, compared 
with the costs of maintaining controlled low-endemic malaria is a must [197, 198]. 
1.9.2.1 Malaria hotspots and hotpops 
A considerable shift in the malaria epidemiology occurs in areas approaching malaria 
elimination due to heterogenic malaria transmission [199]. Malaria infections tend to cluster 
in geographically defined areas (hotspots), typically smaller than 1km
2
, where malaria 
transmission exceeds the average level. Factors determining hotspots are not fully defined, 
but include the proximity to mosquito breeding sites, household structural features, and 
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human behaviour and genetic factors [200]. Clustering also occurs in certain demographic 
high-risk groups (hot populations or hotpops) which are often related to occupation or travel 
[201]. Hotspots and hotpops serve as a source of parasites that fuel subsequent transmission. 
Individual infections are often asymptomatic and subpatent, with parasite densities falling 
beneath the detection level of both microscopy and RDTs, and occurring in hard to reach 
areas. Clustering of asymptomatic parasite carriage determined by PCR and malaria-specific 
immune response determined by serology are robust indicators of hotpots [202, 203]. 
Identifying hotpots and hotpops can be used to target parasite reservoirs effectively and 
achieve maximum impact of control/elimination programmes [200, 204]. 
1.9.2.2 Identifying asymptomatic and subpatent infections 
There are inherent challenges with locating asymptomatically infected individuals as these do 
not seek medical treatment and the infections may often be subpatent especially in low-
transmission settings. However, clearing this parasite reservoir is critical for malaria 
elimination as these individuals still remain infectious to mosquitoes [199, 204, 205]. The 
proportion of subpatent infections appears to increase in areas with recent declines in 
transmission. A meta-analysis showed that microscopy detects as little as 12% of PCR-
detectable infections in areas where PCR prevalence is <10% [206]. Detecting subpatent 
infections requires sensitive molecular diagnostic tools such as PCR or LAMP [65], and still 
very low-density infections may be missed [201, 207]. Synchronised sequestration in P. 
falciparum [208, 209] and hypnozoites in P. vivax and P. ovale also contribute to sub-
microscopic carriage [210]. 
1.9.2.3 Transmissibility of asymptomatic malaria and targeting gametocyte reservoirs  
Some asymptomatic infections may become symptomatic within days or weeks of initial 
detection, but most infections can persist asymptomatically for many months. Single P. 
falciparum clones have shown to circulate for ~200 days before eventually being cleared 
from the bloodstream [65], although the maximum reported duration of a P. falciparum 
infection is 13 years [211]. Sensitive molecular methods have shown that gametocytes are 
detected in most asymptomatic and subpatent infections. Gametocytes comprise <5% of the 
total parasite biomass and are often present in sub-microscopic densities. The transmissibility 
of these infections has been discussed [210]. At least one male and one female gametocyte 
must be taken up in a 2-3µL mosquito blood meal for transmission to occur; transmissibility 
is positively associated with gametocyte density [65]. Human to mosquito transmission rates 
have been estimated to be two to 16 times lower in subpatent compared to patent carriers 
[212], but the high prevalence of subpatent carriers suggest that these are still important 
contributors to the human infective reservoir [65]. Subpatent infections in very low 
transmission setting are estimated to account for 20 to 50% of all human to mosquito 
transmission [205] and can play a significant role in sustaining malaria transmission [213]. 
Although artemisinins possess some gametocytocidal properties which are thought to 
contribute to reduced transmission [214], primaquine is the only currently available drug that 
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actively clears mature P. falciparum gametocytes and prevents malaria transmission. In areas 
of P. falciparum drug resistance or areas targeting malaria elimination, WHO recommend a 
single low-dose (0.25 mg/kg) of primaquine given on the first day of ACT treatment [1]. 
Primaquine induced haemolysis is dose dependent, and the low dose is suggested to be safe 
for G6PD-deficient patients, but high enough to have a gametocytocidal effect and block 
transmission. Before primaquine can be implemented, countries will need to register its use 
and preferably assess the local prevalence and types of G6PD deficiency [215], even within 
the context of low doses which may avoid the need to screen for G6PD deficiency [22]. 
1.9.2.4 Passive versus active surveillance 
Passive case detection relies on health-seeking behaviour of symptomatic individuals to 
reporting health facilities and high test rates. Strong reporting systems are essential in areas of 
malaria control [196, 199], but passive detection alone is unlikely to be sufficient for malaria 
elimination [198]. 
Targeting the asymptomatic reservoir of infections requires active surveillance at a household 
level. Active infection detection can be categorised into reactive and proactive methods. 
Reactive infection detection is triggered when a case is identified by passive case detection 
[198]. It involves visiting the household of the reported case and screening neighbours within 
a defined radius, although there are no standardized guidelines on the size of the screening 
radius. Reactive infection detection is better suited for low transmission settings, especially if 
high risk groups are undefined [202]. Proactive infection detection involves screening of high 
risk populations, without the trigger of a passively identified case, and is more suitable in 
moderate transmission settings. To be successful, active surveillance requires accurate and 
sensitive diagnostic tests. RDTs are often used, but may not be sensitive enough to detect 
asymptomatic carriers limiting the impact of these screening techniques on parasite 
prevalence [202, 216]; LAMP could be a more useful tool in such programmes. High 
coverage of the target population is important for these methods to be successful. To increase 
coverage, whole communities should be screened; those not at home should be recorded and 
revisited where possible [201]. 
1.9.2.5 Mass and focal screening and treatment  
Mass screening and treatment (MSAT) involves screening of all individuals in a given 
geographical area and treatment of those found positive for malaria [190]. Focused screening 
and treatment (FSAT), employs active detection in a smaller geographical area or hotspot, 
and may be triggered by an index case which is followed up by screening contacts of the 
infected individual. FSAT may be more feasible to conduct due to the reduced scope 
compared to MSAT, although FSAT is still labour intensive and requires that an effective 
surveillance system is in place. MSAT and FSAT programmes have had varying results [216, 
217], and have been evaluated as a tactic to contain the spread of artemisinin resistance [218]. 
Both may provide valuable epidemiological information [218], although with a high price tag 
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and logistical difficulties [191]. More research is necessary to determine the long-term and 
cost effectiveness of MSAT and FSAT in a wide range of settings [212]. 
1.9.2.6 Mass drug administration 
Mass drug administration (MDA) is a strategy whereby everybody in a defined geographical 
area or high risk group receives treatment, irrespective of the presence of symptoms and 
without malaria diagnosis [102]. MDA overcomes the issues of missed infections due to 
insensitive diagnostic tools [65, 202] however, the optimum combination of drugs, timing, 
number of rounds per year and total duration of MDA need to be defined [199]. The impact 
of MDA on transmission maybe short lived, especially in high transmission areas. MDA may 
also increase the likelihood of the selection of drug resistance genotypes, and is therefore not 
currently recommended by the WHO. To reduce the risk of resistance emerging, one idea is 
to use different classes of antimalarials for MDA and individual case management [190] 
combined with a transmission limiting treatment such as primaquine [199]. Targeted MDA to 
households or groups identified by passive or active surveillance may be more efficient, and 
high local coverage is more operationally feasible [200]. High degree of community 
participation was identified as a key factor for the successful MDA campaign and elimination 
of P. falciparum and P. vivax on Aneityum island (718 inhabitants), Vanuatu in the 1990’s 
[219]. 
1.9.2.7 Detecting and preventing importation of malaria 
In malaria eliminating settings, imported malaria cases are a critical threat to achieving and 
maintaining elimination [199]. Countries considering elimination should aim to prevent 
importation of infections through proactive case detection at borders. This is however, costly, 
labour intensive and misses subjects crossing unofficial borders and infections which are still 
in the incubation period [201]. 
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1.10 THE CURRENT SITUATION IN ZANZIBAR 
Malaria was the leading cause of death in Zanzibar before scale-up of malaria control 
activities, accounting for more than 50% of in-patient cases and deaths in hospitals. 
Endemicity was moderate to high, with malaria prevalences ranging from 9-50%. In year 
2000, chloroquine had a treatment failure of 60% at 14 days follow-up [220].  
Zanzibar was one of the first regions in sub-Saharan Africa to deploy ACTs to malaria 
patients free of charge through public health facilities. ASAQ and AL were introduced in 
September 2003 as first and second-line treatment of uncomplicated malaria [221]; quinine 
replaced AL as second-line treatment in 2009. LLINs were mass distributed in 2006 to high-
risk groups. The combination of ACT and LLIN deployment resulted in a substantial decline 
in P. falciparum malaria among febrile children, from approximately 30% to 1-2%, and a 
reduction of crude child mortality of approximately 50% between 2003 and 2006 [221]. The 
Zanzibar Ministry of Health implemented malaria control interventions through the Zanzibar 
Malaria Control Programme (ZMCP); the introduction of malaria control interventions are 
presented in Table 2. 
 
Table 2: Introduction of malaria control strategies in Zanzibar [Bjorkman and Shakely et 
al., submitted]. 
Year Interventions 
Nov 2002 Policy decision on introduction of ACTs: 1
st
 line ASAQ, 2
nd
 line ALU 
Sep 2003 ACT deployment in all public health facilities. 
2004 
Limited ITN distribution  
Introduction of intermittent preventive treatment in pregnancy 
Sep 2005 LLIN distribution to all children <5 y and pregnant women 
July 2006 IRS (pyrethroid) rounds aiming at annual universal coverage 
2006 RDT provision to all primary public health facilities. 
2008 LLIN distribution to all (two nets per household) 
2009 New antimalarial treatment policy: 1
st
 line ASAQ, 2
nd
 line Quinine 
2012 
LLIN distribution (two nets per household) 
IRS (carbamate) change – from universal to focal targeting hotspots  
Introduction of malaria case notification and household RDT screening  
 
In 2006, 90% of children under the age of five were reported to sleep under an LLIN [221]. 
Vector control was further strengthened by mass-distribution of two LLINs per household in 
2008-2009, and annual rounds of IRS targeting all households in Zanzibar (excluding Stone 
Town) between 2006 and 2009. Coverage of vector control interventions remained high in 
2009 despite reduced perceived threat of malaria among caretakers, with 70% of under-five 
children reported to sleep under a bed net and 94% living in a house targeted with IRS. 
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Combined, 98% of children were covered by at least one of the vector control methods [222]. 
A study conducted in 2010-2011 reported that 90% of the Anopheles gambiae complex was 
An. arabiensis with a small number of An. gambiae s.s. and An. merus present. An. arabiensis 
in Pemba, but not Unguja, were found to be resistant to Lambda-cyhalothrin, the pyrethroid 
used in LLINs and IRS. Two thirds of LLINs examined were damaged after three years of 
use and insecticide levels were significantly reduced. The study concluded that resistance to 
pyrethroids and the short lived efficacy of LLINs could seriously threaten the sustainability of 
the gains achieved in malaria control in Zanzibar [223]. In 2012, Zanzibar introduced 
Bendiocarb 0.1%, a carbamate insecticide for IRS with focal targeting of hotspots instead of 
universal coverage. 
RDTs were introduced in 2006 for improved case detection, and targeting of treatment to 
patients with confirmed malaria infections. RDTs were shown to improve management of 
fever patients, providing adequate treatment and health outcomes without increased cost per 
patient. Adherence to the test results was high, and resulted in a significantly reduced amount 
of prescribed ACTs as supposed to clinical diagnosis of malaria. [224]. The usefulness of 
RDTs was again assessed in 2010 in the new context of low malaria transmission. This study 
found a test positivity rate of 3.1%; the adherence to test results remained high, but the 
sensitivity of the tests against PCR and microscopy was relatively low (76.5 and 78.8%, 
respectively) [70]. Mass screening and treatment employing RDTs for parasite detection in 
five malaria hotspots in Zanzibar did not reduce subsequent malaria incidence compared with 
controlled areas. These results were most likely due to the low sensitivity of RDTs, and low 
population coverage achieved in the study [216].  
The Malaria Early Epidemic Detection System (MEEDS) was established in Zanzibar in 
2008. MEEDS is a malaria case notification system that involves weekly reporting of 
laboratory confirmed malaria cases using mobile phones. It enables district malaria officers to 
follow-up all malaria cases by reactive case detection, involving testing and treatment of 
index case contacts. MEEDS also enables the tracking of malaria hotspots and resurgences, 
the identifying risk groups, and provides means for procurement assessments and reduces the 
risk of stock outs of RDTs and ACTs in health facilities [220, 225]. 
Zanzibar is presently in a state of malaria pre-elimination. The test positivity rate was 1.3% in 
2010, with 1549 confirmed malaria cases and an approximate API of 1-2 infections per 1000 
individuals [226]. Compiled malariometric indices from two sentinel districts in Zanzibar 
indicate that the major decline in malaria transmission occurred between 2004 and 2007, after 
which there appears to be a steady state of persistent low-level malaria transmission 
[Bjorkman and Shakely et al., submitted]. Zanzibar was first in conducting a malaria 
elimination feasibility assessment in 2009, with the core conclusion that elimination is 
feasible but will be very challenging in Zanzibar [227]. The Zanzibar Ministry of Health has 
declared the goal of malaria elimination and ZMCP officially converted its name to the 
Zanzibar Malaria Elimination Programme (ZAMEP) in August 2013. 
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2 RATIONALE FOR THESIS 
 
The ZMCP (now ZAMEP) has been unique in its success in malaria control. High 
intervention coverage was rapidly achieved after introduction. This achievement was 
probably influenced by comprehensive information to the public and health care staff and a 
strong commitment of the Zanzibar government to rapidly ensure free intervention coverage. 
Furthermore, Zanzibar residents have, in general, easy access to public health facilities 
located within 5km from any community and served by good public transport [222]. 
However, as presented in this comprehensive literature review, the transition from malaria 
control to malaria elimination will require additional components such as surveillance and 
response systems that are able to detect and eliminate residual reservoirs of symptomatic and 
asymptomatic infection. Such systems will need more sensitive diagnostic tools than those 
that are already available, such as PCR and genotyping for molecular surveillance of parasite 
prevalence and genetic markers of drug resistance. 
The rapid transition from high malaria transmission to pre-elimination in Zanzibar during the 
last decade provides a unique research opportunity to study how molecular methods may 
assist malaria elimination efforts in a pre-elimination setting. Karolinska Institutet has since 
2001 acted as the main scientific partner of ZMCP/ZAMEP with two main study sites in 
Zanzibar: North A (Unguja Island) and Micheweni (Pemba Island) districts (Figure 5). 
Longitudinal samples collected in these study sites, as well as samples collected throughout 
Zanzibar, have been used in this PhD-programme to gain insight into the application of 
molecular methods for improved malaria surveillance and control. 
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4 AIMS AND OBJECTIVES 
 
4.1 OVERALL AIM OF THE THESIS 
To gain insight into the application of modern molecular methods for enhanced malaria 
infection detection and surveillance of antimalarial drug resistance in a pre-elimination 
setting such as Zanzibar. 
 
 
4.2 SPECIFIC OBJECTIVES 
Study I: To assess whether prolonged use of ASAQ as first-line antimalarial treatment 
selects for P. falciparum SNPs associated with resistance to the ACT partner drug 
amodiaquine. 
Study II: To evaluate different methods of DNA extraction from RDTs and to assess whether 
RDTs collected under field conditions could preserve parasite DNA for the purpose of 
molecular epidemiological investigations. 
Study III: To evaluate the performance of a new, highly sensitive SYBR Green qPCR-RFLP 
assay for Plasmodium detection and species determination. 
Study IV: To characterise temporal trends and transporter polymorphisms in asymptomatic 
Plasmodium infections during the transition from high to low transmission in Zanzibar. 
Study V: To report results from the hitherto largest implementation of LAMP in the field, for 
scaled up, centralised mass-screening of asymptomatic malaria in Zanzibar. 
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5 MATERIAL AND METHODS 
 
5.1 STUDY LOCATION AND POPULATION 
All studies included in this thesis were conducted in Zanzibar, an archipelago located 
approximately 35 km off the coast of Tanzania in East Africa (Figure 5A). Zanzibar consists 
of two main islands, Unjuga and Pemba, with respective populations of approximately 
900,000 and 400,000. Subsistence farming and fishing are the main occupations; ~40% of the 
population live below the basic needs poverty line [228]. Malaria transmission is perennial 
with two peaks associated with seasonal rainfalls in March-June and October-November. P. 
falciparum is the predominant malaria species; Anopheles gambiae and An funestus are 
considered the main vectors. ASAQ was introduced as the first-line malaria treatment in 
September 2003 [229]. 
Samples for Studies I-IV were collected in two sentinel districts in Zanzibar, North A 
(Unguja Island) and Micheweni (Pemba Island) (Figure 5B). Both districts are rural with a 
population of approximately 100,000 people each. Both districts have one Primary Health 
Care Centre (PHCC), which provides in- and outpatient care, and 12 public Primary Health 
Care Units (PHCUs), where basic medical management is provided. Two private health 
facilities have been established in each district in recent years [70]. Study V was conducted in 
10 districts throughout Zanzibar (6 in Unguja and 4 in Pemba). 
 
 
Figure 5: A) Map of Zanzibar, East Africa. B) Map of North A and Micheweni districts 
(highlighted in red).  
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5.2 SAMPLE COLLECTION 
5.2.1 Clinical studies 
ACO I: A clinical trial comparing the efficacy of ASAQ and AL, before the implementation 
of ASAQ and AL as first and second-line treatments in Zanzibar, respectively. The trial was 
conducted in children under the age of five, during November 2002 and February 2003, in the 
two PHCCs in North A and Micheweni district [230]. Inclusion criteria were age 6-59 
months, parasitaemia levels of 2000-200,000 asexual parasites/µL blood and axillary 
temperatures of ≥37.5ºC at the time of enrolment or history of fever during the preceding 24 
hours. Exclusion criteria were symptoms or signs of severe disease. Blood samples collected 
on filter paper on day 0 of the study (prior to treatment with antimalarial drugs) were used in 
Study I. 
RDT-ACT: A study aimed to evaluate the usefulness of an PfHRP2 based RDT in the hands 
of primary health care workers, for detection of P. falciparum in fever patients of all ages 
[70]. The study was conducted during May-July 2010, in 12 public health facilities, six each 
in North A and Micheweni districts. Inclusion criteria were all ages ≥2 months, presenting at 
the study sites with fever (≥37.5ºC at the time of enrolment or history of fever during the 
preceding 24 hours). Exclusion criteria were symptoms or signs of severe disease. The study 
is registered on ClinicalTrials.gov with study identifier “NCT01002066”. Blood samples 
collected on filter paper and RDTs were used in Study I and II. 
 
5.2.2 Cross-sectional household surveys 
Cross-sectional household surveys have been conducted during the period May-July on an 
annual or biannual bases in North A and Micheweni districts since 2003 to monitor 
community prevalence of malaria and uptake of malaria control interventions [221], 
[Bjorkman and Shakely et al., submitted]. Shehias (the smallest administrative units in 
Zanzibar) were randomly selected from the two districts in 2003; households in each shehia 
were randomly selected for each survey. Sample size was based on the estimated proportion 
of children <5 years with malaria parasitaemia in 2003; sample sizes remained similar in 
subsequent surveys. 
Household visits were conducted by trained health personnel. Finger prick blood samples for 
malaria screening by microscopy or RDT were collected from healthy individuals, of all ages, 
present during the surveys. In addition, blood samples were collected (from the same finger 
prick) on filter paper for molecular analyses. Epidemiological data in forms of demographic 
and clinical information were also collected at each survey. Microscopy/RDT data and blood 
samples collected on filter paper from 2005, 2009, 2011 and 2013 were used in Study III and 
IV (where referred to as asymptomatic samples). 
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5.2.3 Collection of RDTs at public health facilities 
Primary health care facilities in North A and Micheweni district were asked to passively 
collect positive RDTs from fever patients attending the clinic. They were asked to record age, 
date and health facility on the back of the RDT device. RDTs collected during Jan-July 2013 
were used in Study IV (where referred to as symptomatic samples). 
 
5.2.4 Deployment of LAMP in the field and KAPB survey 
LAMP was deployed as part of a larger study regarding knowledge, attitude, practice and 
behaviour (KAPB) towards malaria [Cook et al., unpublished data], a cross-sectional 
household survey conducted in ten districts throughout Zanzibar (six in Unguja and four in 
Pemba) in April-May 2014. Household visits were carried out in 60 villages. Tablet 
computers were used to conduct questionnaires in each household. All individuals present 
and willing to participate in the randomly selected households were screened for malaria by 
RDT. In every other household, participants were asked to provide 60µL of finger prick 
blood for LAMP screening. RDT results and whole blood samples were used in Study V. 
 
5.2.5 In vitro parasite culture and generation of dilution series 
For the purpose of evaluating molecular methods, dilutions series of known parasite densities 
were generated from in vitro cultured 3D7 P. falciparum parasites and P. vivax, P. malariae 
and P. ovale blood samples from patients diagnosed and treated at the Karolinska University 
Hospital, Stockholm, Sweden. Tenfold dilution series were prepared, in fresh uninfected 
whole blood. Dilution series were used in Study II and III, and in Study IV for determining 
parasite densities. 
 
5.2.6 Collection and storage of blood samples on filter paper and RDTs 
Dried blood spots on filter paper have been widely used in field studies as the DNA is 
relatively well preserved, and the samples are easy to transport to laboratory settings without 
the need for a cold chain [231]. Finger prick samples (approximately 50-100μL) were 
collected on filter papers (3MM

, Whatman, United Kingdom), air dried and individually 
packaged in plastic envelopes with desiccants. 
Several studies have shown that RDTs are a reliable source for parasite DNA preservation 
[37, 48, 50]. RDTs were performed according to the manufacturer’s instructions and allowed 
to air dry before storing without desiccants. 
All samples were stored at room temperature (<25ºC) and shipped to Karolinska Institutet, 
Stockholm, Sweden, for molecular analyses. 
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5.2.7 Data entry 
Data collected in clinical trials and cross-sectional surveys (apart from in 2013) were double-
entered in Microsoft Access or CSPro and validated using Excel. Data collected in the cross-
sectional survey in 2013 and the field deployment of LAMP in 2014 were entered using 
Nexus 7 tablet computers as the studies were conducted. 
 
5.2.8 Ethical considerations 
All field studies were performed in accordance with the Declaration of Helsinki [232] and 
Good Clinical Practice [233]. Informed consent was obtained from all study participants, or 
from parent/guardians of children, prior to study enrolment. Ethical approvals were obtained 
from the ethical committees in Zanzibar at the time of the trials, the Regional Ethics 
Committee in Stockholm, Sweden and the Medical Ethics Committee at Karolinska Institutet, 
Stockholm, Sweden. 
 
5.3 DIAGNOSTIC TOOLS 
5.3.1 Blood slide microscopy 
Examination of thick blood smears was conducted by experienced microscopists in Zanzibar 
according to standard WHO procedures [221], [Bjorkman and Shakely et al., submitted]. 
Thick blood films were stained with 5% Giemsa for 30 minutes and parasite densities were 
calculated against 200 white blood cells. If fewer than ten parasites were detected, 
examinations were extended to 500 white blood cells. Blood slides were considered negative 
if no asexual parasites were found in 200 high-power fields. Quality control (independent 
second reading) was conducted for all positive slides as well as 10% of the negative slides. 
Blood slide microscopy was used in the cross-sectional surveys conducted in 2005 and 2009 
(Study IV). 
 
5.3.2 RDT devices 
Three RDT devices have been used in this theses: Paracheck-Pf
® 
(Orchid Biomedical 
Systems, India), SD-Bioline Malaria Ag P.f/Pan
®
 (Standard Diagnostic, Republic of Korea), 
and First Response Malaria Ag Combo (pLDH/HRP2) (Premier Medical Corporation Ltd., 
India).  
Paracheck-Pf, a PfHRP2 based RDT, has been widely used in sub-Saharan Africa, and was 
the first RDT to be implemented in Zanzibar in 2006. Zanzibar recently changed to SD-
Bioline P.f/Pan, as this test also detects species other than P. falciparum. Both SD-Bioline 
P.f/Pan and First Response Malaria Ag Combo (pLDH/HRP2) are combo RDTs detecting 
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both PfHRP2 and pLDH. RDTs were conducted according to the manufactures’ instructions 
in Study II, IV and V. 
 
5.4 DNA EXTRACTION METHODS 
5.4.1 DNA extraction from dried blood spots on filter paper 
5.4.1.1 Sample preparation 
Filter paper disc/discs of Ø 3 mm with blood saturated on both sides (≈ 3-5 µL blood/disc) 
was/were cut into 1.5 ml safe-lock tubes with manual paper punchers rinsed in water and 
ethanol in between samples. Extracted genomic DNA was stored at -20°C until use (Studies 
I-IV). 
5.4.1.2 ABI PRISM 6100 extraction 
ABI PRISM 6100 Nucleic Acid PrepStation
TM 
with NucPrep reagents is a system that uses 
96-well filtration plates containing a glass fibre membrane, and a small benchtop vacuum 
manifold (Applied Biosystems, USA). Samples were lysed with Proteinase K. Cell lysates 
were passed through the glass fibre membrane, one sample per well. The membrane was 
washed, and high quality DNA eluted in a two-step elution buffer system. The yield of DNA 
is 70-90% on a per cell basis and is optimal for 150µL fresh or frozen blood. DNA was 
extracted from three 3mm filter paper discs (≈ 15µL blood) following the protocol for 
“isolation of DNA from fresh or frozen whole blood” [234] with some minor modifications 
[235]. The final DNA containing elution volume was 200µL (Study I and II).  
5.4.1.3 Chelex-100 extraction  
Chelex-100 is a boil and spin method with the addition of Chelex-100, a chelating resin that 
binds cations such as Mg
2+
 protecting the DNA from degradation by DNAases. Samples were 
lysed in Saponin. DNA was extracted from one 3mm filter paper disc as described by 
Wooden et al. (1993) [236] with minor modifications. The final DNA containing elution 
volume was ~90µL (after deduction of 10% Chelex-100 from a total volume of 100µL) 
(Study III and IV). 
5.4.1.4 QIAmp DNA mini kit 
The QIAamp DNA mini kit (Qiagen Gmbh, Germany) provides silica membrane-based 
nucleic acid purification with a spin-column procedure. Recovery of DNA from older 
samples has been shown to be somewhat improved by the use of commercial DNA 
purification columns [231]. Samples were lysed with Proteinase K. DNA was extracted from 
three 3 mm filter paper discs according to the protocol “DNA purification from dried blood 
spots” [237]. The final DNA containing elution volume was 150µL (Study IV, for re-
extraction of samples collected in 2005). 
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5.4.2 DNA extraction from RDT 
5.4.2.1 Sample preparation 
RDT cassettes were opened using a thin metal spatula. The nitrocellulose strip, containing the 
equivalent of ~5µL blood, was held at the buffer pad with forceps and cut into 3 x 3 mm 
pieces using scissors. The forceps and scissors were washed in 70% ethanol and dried on 
clean tissue paper in between each sample to minimise cross-contamination during sample 
preparation. RDT preparation was in accordance with WWARN guidelines [238]. Extracted 
genomic DNA was stored at -20°C until use (Study II and IV). 
5.4.2.2 Simple elution 
The simple elution method for DNA extraction from RDTs involves boiling the proximal part 
of the nitrocellulose strip in molecular grade water followed by centrifugation [37]. Samples 
are lysed in the buffer provided with the kit during the performance of the RDT. DNA is 
captured on the proximal end of the nitrocellulose membrane separating the DNA from the 
cell lysate that contains PCR inhibitors such as haem. This crude method of DNA extraction 
works better for some RDTs than others; a plastic film covering the nitrocellulose strip seems 
to hamper the release of DNA during boiling. The final DNA containing elution volume was 
50µL (Study II). 
5.4.2.3 ABI PRISM 6100 extraction  
ABI PRISM 6100 extraction from RDTs is based on the same protocol as for filter papers, 
but with some further modifications involving lyses of the biological samples in three-fold 
volume of NucPrep reagents, and separating the solid material from the lysate by passing the 
content through a 5 mL syringe. The final DNA containing elution volume was 200µL (Study 
II). 
5.4.2.4 Chelex-100 extraction 
Chelex-100 extraction from RDTs is based on the same principle as for filter papers, 
involving an overnight incubation in saponin followed by boil and spin with the addition of 
Chelex-100 [239]. The final DNA containing elution volume was ~190µL (after deduction of 
5% Chelex-100 from a total volume of 200µL) (Study II and IV). 
 
5.4.3 DNA extraction from whole blood 
5.4.3.1 Simple boil and spin 
The simple boil and spin method was used for extraction of DNA from 60mL whole blood in 
conjunction with LAMP according to protocol [240]. This crude method of extraction works 
well with LAMP, as LAMP is less prone to inhibition than PCR [79] (Study V). 
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5.5 MOLECULAR METHODS 
5.5.1 PCR for detection of Plasmodium species 
5.5.1.1 Nested PCRS 
18S rRNA nested PCR (18S-nPCR): Snounou et al. (1993) [54, 55] established one of the 
earliest nested PCR methods targeting the 18S rRNA sequences of Plasmodium species. This 
method allows for Plasmodium species detection using pan-Plasmodium primers, and 
Plasmodium species determination (in pan-Plasmodium PCR positive samples) by four 
additional PCRs using species-specific nested primers (Study II and III). 
Cytb nested PCR (cytb-nPCR): Steenkeste et al. (2009) [57] established a nested PCR 
targeting the cytb gene of the four major human Plasmodium species. This method was 
further modified by Hsiang et al. (2010) [52] for use of restriction fragment length 
polymorphism (RFLP) analysis with AluI enzyme for species determination (Study II and 
III). 
5.5.1.2 Gel electrophoresis 
Nested PCR products were visualised under UV transillumination after gel electrophoresis on 
1.5-2.5% agarose stained with ethidium-bromide or GelRed, and documented with a 
GelDoc
TM
 system (Study I-IV). 
5.5.1.3 Real-time quantitative PCR  
18S rRNA probe-based real-time PCR (18S-qPCR-R): Rougemont et al. (2004) [62] 
developed a probe-based qPCR targeting the 18S rRNA sequences of Plasmodium species. 
Plasmodium species were detected using pan-Plasmodium primers and probe. PCR positivity 
was defined as quantification cycle (Cq) values below 40 (Study II and III). The method also 
allows for species determination by additional qPCRs using species-specific probes, and was 
adapted for multiplexed detection of single and mixed-species infections by Shokoples et al. 
(2009) [63] (Study II).  
18S rRNA probe-based real-time PCR (18S-qPCR-K): Kamau et al. (2011) [61] also 
developed a genus-specific probe-based qPCR targeting the 18S rRNA sequences of 
Plasmodium species. PCR positivity was defined as Cq values below 40. This method is 
designed for pan-Plasmodium detection only, and does not allow for species determination 
(Study II and III). 
Cytb-qPCR assay (cytb-qPCR): We developed a SYBR Green real-time PCR restriction 
fragment length polymorphism assay targeting the cytb gene of the four major human 
Plasmodium species (P. falciparum, P. vivax, P. malariae, and P. ovale) [Xu et al., in press]. 
Positivity was confirmed by gel-electrophoresis on a 1.5% agarose gel stained with GelRed. 
Plasmodium species was determined by RFLP on positive cytb-qPCR products (Study III and 
IV).  
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5.5.2 Quantitative PCR 
5.5.2.1 Parasite densities estimated by qPCR  
Parasite densities were estimated by a modified version of the 18S-qPCR-K (described 
above) [61].
 
In brief, positive samples were subjected to the 18S-qPCR-K using published 
protocol, primers and probe. Parasite densities were determined against a standard curve 
generated by a Chelex-100 extracted, 10-fold P. falciparum and P. malariae dilution 
series (10,000-1 p/µL) spotted on filter paper (Study IV).  
5.5.2.2 Determining Pfmdr1 copy number 
Pfmdr1 copy number has been associated with resistance to mefloquine, lumefantrine and 
artemisinins [116]. Pfmdr1 copy number was determined by the comparative ΔΔCq method 
following a TaqMan
®
 probe-based real-time multiplex qPCR, with a Cq cut-off of 35 [124]. 
The multiplex qPCR amplified the target gene (pfmdr1) and a reference gene (β tubulin) 
which is present in only one copy. A strain of P. falciparum with a single copy of pfmdr1 
(3D7) was used as a calibrator and a strain with more than one copy of pfmdr1 (Dd2) was 
used as a multicopy control. P. falciparum with multiple copies of pfmdr1 are rare in East 
Africa [241]; the method was used in Study II as an assessment of the quality of the extracted 
DNA. 
 
5.5.3 Nested PCR-RFLP for genotyping of SNPs 
Samples containing P. falciparum were genotyped for SNPs associated with amodiaquine 
resistance at positions pfcrt K76T, pfmdr1 N86Y, Y184F and D1246Y by previously 
described nested PCR-RFLP methods [242-244]. Lab clones 3D7, Dd2 and 7G8 were used as 
positive and negative restriction controls (Study I, II and IV). 
5.5.3.1 Mixed infections 
An infection was defined as mixed if both alleles were present at a particular locus during 
RFLP. Mixed infections were dealt with differently in each study. In Study I a mixed 
infection was considered to contain two P. falciparum strains, each contributing one allele to 
the wild type and mutant allele frequency. This method may be biased since the multiplicity 
of infection (MOI) was unknown. In Study II the mixed infections were analysed as a 
separate group. In Study IV SNP frequencies were defined as the proportion of isolates 
containing alleles associated with antimalarial drug resistance (including mixed infections).  
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5.5.4 Other molecular methods 
5.5.4.1 Nested PCR and sequencing for screening pfkelch13 SNPs 
A nested PCR protocol published by Ariey et al. (2014) [152] was used to amplify a 850bp 
fragment of the kelch propeller domain with Q5 high-fidelity polymerase (New England 
Biolabs, UK) [152]. Direct Sanger sequencing of the PCR product was performed by 
Macrogen in the forward direction only (Additional results). 
5.5.4.2 Microsatellite analysis 
Microsatellite analysis was used to estimate the MOI, i.e. the number of different P. 
falciparum strains present in a single infection, and to estimate the heterozygosity as a 
measure of genetic diversity. Seven previously published microsatellites were analysed by 
capillary electrophoresis [245, 246] (Study IV). 
5.5.4.3 Loop-mediated isothermal amplification (LAMP) 
LAMP was conducted by technicians in Zanzibar with limited or no experience of molecular 
methods. The technicians were provided with three and a half days of training. DNA was 
extracted by the boil and spin method [240]. The LAMP assay was performed with 
Loopamp
TM
 MALARIA Pan/Pf Detection Kit (Eiken Chemical Company, Japan) as per 
protocol [240]. Samples positive for Pan-LAMP were retested with Pf-LAMP (Study V). 
 
5.6 BIOINFORMATICS 
The web-based software Primer3 v.0.4.0 (http://frodo.wi.mit.edu/) was used for designing 
primers targeting a conserved area in the cytb gene of the four major human Plasmodium 
species for the cytb-qPCR assay. The NCBI primer-blast function 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to assess primer specificity 
(Study III). PlasmoDB version 9.3 (http://plasmodb.org/plasmo/) and the NCBI database 
(http://www.ncbi.nlm.nih.gov/) were used to obtain gene sequences. Sequencer version 5.0 
(Gene Codes Co, Arbor, MI) and ClustalW2 software 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) were used to align DNA sequences, primers and 
probes (Study II and Additional results). 
 
5.7 STATISTICAL ANALYSES 
Statistical analyses were conducted using SigmaPlot
®
 11.0 (Systat Software Inc, USA) or 
Stata/SE 12.0 (StataCorp LP, USA). Statistical significance was determined as p<0.05 in all 
studies.  
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Table 3: Summary of methods used in each study. 
 
 
Study I Study II Study III Study IV Study V 
Sample 
collection 
Aco I and 
RDT-ACT 
studies 
Dilution series 
and RDT-ACT 
study 
Dilution series 
and 2011 cross-
sectional 
survey 
2005, 2009, 
2011 and 2013 
cross-sectional 
surveys; RDTs 
collected at 
health facilities 
LAMP 
deployment 
study 
Sample 
material 
Filter paper Filter paper 
and RDTs 
Filter paper Filter paper 
and RDTs 
Whole blood 
DNA 
extraction 
ABI PRISM Simple 
elution; 
Chelex-100; 
ABI PRISM 
Chelex-100 Chelex-100; 
Qiamp DNA 
mini kit 
Simple boil 
and spin 
PCR for 
detection of 
Plasmodium 
 18S-nPCR; 
cytb-nPCR; 
18S-qPCR-K; 
18S-qPCR-R 
18S-nPCR; 
cytb-nPCR; 
18S-qPCR-R; 
18S-qPCR-K; 
Cytb-qPCR 
Cytb-qPCR  
PCR for 
genotyping 
resistance 
markers 
Nested PCR-
RFLP for 
genotyping 
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6 RESULTS AND DISCUSSION 
 
6.1 STUDY I 
Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine 
despite its wide scale use as ACT partner drug in Zanzibar 
Gabrielle Fröberg, Louise Jornhagen, Ulrika Morris, Delér Shakely, Mwinyi I. Msellem, José 
P. Gil, Anders Björkman and Andreas Mårtensson 
The aim of this study was to assess whether prolonged use of ASAQ as first-line antimalarial 
treatment selects for P. falciparum SNPs associated with resistance to the ACT partner drug 
amodiaquine. This was assessed by comparing the prevalence of pfcrt 76T, pfmdr1 86Y, 
Y184 and 1246Y SNPs and the pfcrt K76T / pfmdr1 N86Y, Y184F, D1246Y haplotypes in 
2002-2003, before the implementation of ASAQ as first-line treatment, and seven years after 
wide scale use of ASAQ in 2010. Prevalences were compared by chi-square test. 
The main findings from this paper include: 
 A significant decrease in the prevalence of pfcrt 76T (96–63%; p<0.001), pfmdr1 86Y 
(75–52%; p<0.001), Y184 (83–72%; p=0.024), 1246Y (28–16%; p=0.020), despite 
wide scale use of ASAQ (Figure 6). 
 A significant decrease in the most common pfcrt K76T / pfmdr1 N86Y, Y184F, 
D1246Y haplotypes pfcrt/pfmdr1 TYYD (46–26%; p<0.001) and TYYY (17–8%; 
p=0.017). 
 A significant increase of pfcrt/pfmdr1 KNFD (0.4–14%, p<0.001) and KNYD (1–
12%; p<0.001) haplotypes. 
 
 
 
 
 
 
 
Figure 6: SNP frequencies in Zanzibar before (2002-2003) and seven years after (2010) 
ASAQ implementation. Asterisk (*) and (**) indicate p values below 0.05 and 0.001, 
respectively.  
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Four hypotheses were put forward as potential contributing factors to these results: 
 Genetic dilution by imported P. falciparum parasites from mainland Tanzania [247]. 
The current first-line treatment in Tanzania is AL, which has shown to select the 
opposite alleles as ASAQ, i.e. pfcrt K76, pfmdr1 N86, 184F and D1246 [116].  
 Selection by artesunate per se. Pfcrt K76, pfmdr1 N86 and D1246 have been 
associated with decreased susceptibility to artemisinins in vitro, but not in vivo [146-
149].  
 Fitness costs of SNPs associated with amodiaquine resistance. Malaria transmission 
was higher in 2002-2003 when chloroquine was the first-line treatment. The higher 
frequency of malaria treatments and higher re-infection rates resulted in a greater drug 
pressure for selection of SNPS. In 2010 the malaria prevalence was lower, with lower 
treatment frequency, and reduced risk of re-infections after ASAQ treatment. The 
fitness cost of the SNPs and TYYD/TYYY haplotypes would have been greater in the 
new epidemiological context. 
 Finally, the association between these SNPs and amodiaquine resistance may not be 
strong enough for selection of mutations after wide scale use of ASAQ. The rapid 
reduction in parasite load and gametocytocidal properties of artesunate may protect 
against the selection of SNPs by reducing the exposure to amodiaquine and by 
reducing transmission of resistant parasites [214]. In a later study, a pooled analysis of 
individual patient data, none of the analysed pfcrt or pfmdr1 parasite genotypes were 
significant risk factors for recrudescent infections (treatment failures), but pfmdr1 
86Y and 1246Y were selected in re-infections after treatment with ASAQ [116], 
confirming this hypothesis. 
A decrease in the prevalence of SNPs previously associated with amodiaquine resistance was 
observed. ASAQ as first-line treatment did not selected for SNPs associated with 
amodiaquine resistance in febrile patients, despite seven years of wide scale use. These 
unexpected results may indicate sustained efficacy of this ACT [248] as first-line treatment in 
Zanzibar, but require more elaborate studies of temporal trends of molecular markers 
associated with ASAQ resistance both among symptomatic and asymptomatic P. falciparum 
infections, to improve the understanding of the observation. 
A limitation of this study includes the way mixed infections were dealt with in the analysis of 
SNPs. Mixed infections were considered to contain two P. falciparum strains, contributing 
with one of each SNP alleles during PCR-RFLP. However, since the true MOI was unknown, 
this could potentially introduce a bias, especially since the MOI was likely to be higher in 
2002-2003 due to higher transmission than in 2010. Ideally the analyses should have been 
repeated after removing the mixed infections to ensure that these were not biasing the results. 
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6.2 STUDY II 
Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria -
assessment of DNA extraction methods and field applicability 
Ulrika Morris, Berit Aydin-Schmidt, Delér Shakely, Andreas Mårtensson, Louise Jörnhagen, 
Abdullah S. Ali, Mwinyi I. Msellem, Max Petzold, José P. Gil, Pedro Ferreira and Anders 
Björkman 
The aim of this study was to compare and evaluate different methods of DNA extraction from 
used RDTs and to assess whether RDTs collected under field conditions could preserve 
Plasmodium DNA for the purpose of molecular malaria surveillance. Three methods of DNA 
extraction were compared under laboratory conditions in two RDT devices (Paracheck-Pf® 
and SD Bioline Malaria Pf/Pan®). Paired RDT (Paracheck-Pf) and filter paper (Whatman® 
3MM) blood samples (734 RDT negative and 121 RDT positive samples) collected from 
febrile patients in Zanzibar were used to assess the field applicability. RDT positive samples 
were genotyped at single nucleotide polymorphisms (SNPs) in pfmdr1 and pfcrt as well as for 
pfmdr1 copy number. Genotyping outcomes were compared by kappa (κ) analysis and qPCR 
Cq values were compared by Wilcoxon rank-sum test. 
The main findings from this paper include: 
 The DNA detection limit varied with RDT device and extraction method. Chelex-100 
extraction performed best for all extraction matrixes (table 4). Increasing the size of 
the fragment of the nitrocellulose strip did not generally improve the level of 
detection. DNA extraction from RDTs was equal to or better than an equal volume 
(5µL) of blood spotted on filter paper. 
 There was no significant difference in PCR detection rates in DNA extracted from 
RDT and filter paper. In total 118 (13.8%; CI95% 11.4-16.2) field samples were PCR 
positive in both RDTs and filter paper (κ=0.94). 
 There were no significant differences in the PCR success rates or the genotyping 
outcomes for the respective SNPs in the 121 RDT positive samples (Figure 7). There 
was no significant difference in the ability to detect mixed infections or in the Cq 
values (when assessing pfmrd1 copy number) in the RDT and filter paper samples. 
Table 4: Summary of RDT-DNA extraction sensitivity (parasites/µL) under laboratory 
conditions. § = not determined due to negative results. 
 Paracheck-Pf SD Bioline Pf/Pan Filter paper 
Simple elution § 2 200 
Chelex-100 2 2 2 
ABI 6100  20 20 200 
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Figure 7: Genotyping outcomes for RDT and filter paper extracted DNA at SNPs in 
pfmdr1 and pfcrt. Blue colour represents pfcrt K76, pfmdr1 N86, Y184 and D1246; red 
represents mixed infections; green represents pfcrt 76T, pfmdr1 86Y, 184F and 1246Y. 
We provided a comprehensive comparative study of three DNA extraction methods and 
found that the method, the design of the RDT, and the choice of PCR, all affected the 
sensitivity of extraction: 
 Simple elution, although cheap, did not work well for DNA extraction from 
Paracheck-Pf and its use is maybe limited by RDT design and choice of PCR.  
 Chelex-100 extraction, a relatively inexpensive but moderately labour-intensive 
method, preformed best in all extraction matrixes and could be particularly suitable 
for low-density infections. One concern is the storage capacity of Chelex-100 
extracted DNA which may be more susceptible to DNA degradation during freeze-
thawing.  
 The ABI 6100 extraction method had higher sensitivity, but provided high quality 
DNA although at a substantial cost and requiring specialised equipment. The ABI 
6100 method provided adequate results for the analysis of molecular markers of drug 
resistance in RDT positive fever patients.  
RDTs delivered DNA of equal quality as filter papers suggesting that RDTs are a valuable 
alternative for DNA storage under field conditions. RDTs offer multiple logistical advantages 
during sample collection, such as providing diagnosis and blood sample from the same finger 
prick and providing protection from cross-contamination by its plastic case. However, RDTs 
provide limited amount of biological material (usually 5µL of blood compared to 50-100µL 
on filter paper) and no possibility for re-extraction. Wide scale collection of RDTs is being 
implemented as an integral part of molecular surveillance of malaria in Zanzibar. 
A limitation with this study is the use of detection limits as a surrogate for DNA 
concentration when comparing the DNA extraction methods under laboratory conditions, and 
that the different extraction volumes were not taken into consideration. The Cq values 
provided by the 18S-qPCR-K method showed inconclusive results when comparing the 
Chelex-100 and ABI extracted samples. Ideally the in vitro experiments should have been 
repeated and analysed by qPCR in triplicate.  
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6.3 STUDY III 
SYBR Green real-time PCR-RFLP assay targeting the Plasmodium cytochrome b gene 
– a highly sensitive molecular tool for malaria parasite detection and species 
determination 
Weiping Xu, Ulrika Morris, Berit Aydin-Schmidt, Mwinyi Msellem, Delér Shakely, Max 
Petzold, Anders Björkman and Andreas Mårtensson 
The aim of this study was to evaluate the performance of a new, highly sensitive SYBR 
Green qPCR targeting the cytb gene of the four major human Plasmodium species, and RFLP 
assay for species determination (cytb-qPCR). The cytb-qPCR was primarily developed for 
detection of low-density malaria infections, in DNA extracted with Chelex-100 from samples 
collected on filter paper. The performance of the cytb-qPCR was evaluated against four 
reference PCR methods [56, 57, 61, 62] under laboratory conditions, and in 2977 samples 
collected in a cross-sectional survey conducted 2011 in Zanzibar. Field samples were defined 
as ‘final positive’ if positive in at least two of the five PCR methods. The individual PCRs 
were compared against the ‘final positive’ samples by McNemar’s exact test and kappa 
analysis; sensitivity and specificity were also calculated.  
The main findings from this study include: 
 The cytb-qPCR performed equal to, or better than the reference PCR methods, with a 
parasite detection limit of 1-2 parasites/µL, robust PCR amplification efficiency 
(98.2-110.4%), a sensitivity of 100% (CI95% 94.5-100%) and specificity of 99.9% 
(CI95%, 99.7-100%), and could reliably determine Plasmodium species by RFLP. 
 The cytb-qPCR was proven specific by gel electrophoresis, primer-blast analysis of 
the cytb-qPCR primers against the NCBI nucleotide and chromosome database, and 
in malaria negative samples. 
 The cytb-qPCR had 100% reproducibility in parasite densities ≥10 parasites/µL. For 
parasite densities of 1 or 2 parasites/µL, the cytb-qPCR was reproducible in four to 
six out of eight replicates. 
 Comparable detection limits to those previously reported with the 18S-qPCR-K and 
cytb-nPCR (0.05 and 0.075 parasites/µL, respectively) were obtained with the cytb-
qPCR with one fortieth of the biological material (3-5µL blood as opposed to 200µL 
in extraction from whole blood). 
 There was high level of agreement (κ=0.86-0.98), high sensitivity (89.2-100%) and 
high specificity (99.6-100%) between the 18S-qPCR-K, cytb-nPCR, cytb-qPCR and 
the ‘final positive’ samples. The 18S-nPCR found a significantly lower number of 
PCR positives (p<0.01) resulting in a lower sensitivity (49.2%; CI95% 36.6-61.9). 
The 18S-qPCR-R had a significantly higher number of PCR positives (p<0.01) 
resulting in a lower specificity (86.6%; CI95% 85.3-87.8). 
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 The discrepancies between the PCR methods may be explained by variations in PCR 
product size, target gene copy number and PCR primer and probe binding sites. The 
18S-nPCR has a substantially larger first PCR product which may reduce the PCR 
efficiency. The cytb gene (present in mitochondrial DNA) is likely to have a higher 
copy number than 18S rRNA genes, and mitochondrial DNA may be better preserved 
than genomic DNA. The low specificity of the 18S-qPCR-R may be due to unspecific 
amplification and/or probe degradation at high quantification cycle numbers. And 
finally, it was observed in the sequence alignments of the 18S rRNA genes that the 
species-specific 18S-nPCR and 18S-qPCR-R only targeted two to three copies of 18S 
rRNA genes, potentially reducing the sensitivity of these species-specific PCRs, 
whilst the cytb PCRs targeted conserved regions of the four major human 
Plasmodium species equally. 
 
Although the cytb-qPCR performed well, there are several limitations with this method and 
study:  
 Importantly the cytb-qPCR requires gel-electrophoresis for determining positive 
samples and RFLP for species determination. An ideal method would both detect and 
determine species in a single qPCR. This was not possible for the cytb-qPCR due to 
the high AT content of the amplified product, precluding the use of melting 
temperatures to determine positive samples and Plasmodium species. 
 There is no optimal statistical tool for comparing multiple methods. In the absence of 
an appropriate gold standard a conservative approach was used; the individual PCR 
methods were compared against ‘final positive’ samples defined as being positive in 
at least two of the five PCRs. 
 Finally, the detection limits were based on dilution series of blood samples with 
parasite densities determined by microscopy. Although rigorous methods were 
applied to obtain as accurate parasite densities as possible, the accuracy of assessing 
the detection limits may be doubtful. Perhaps the use of standard dilution series with 
defined parasite densities [249], or exact copy numbers of plasmid DNA could have 
circumvented this. However, the comparative analytical sensitivity between the 
methods still stands for DNA extracted from filter paper.  
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6.4 STUDY IV 
Characterising temporal trends in asymptomatic Plasmodium infections and 
transporter polymorphisms during transition from high to low transmission in 
Zanzibar 
Ulrika Morris, Weiping Xu, Mwinyi I. Msellem, Alanna Schwartz, Ali Abass, Delér Shakely, 
Jackie Cook, Achuyt Bhattarai, Max Petzold, Bryan Greenhouse, Abdullah S. Ali, Anders 
Björkman, Gabrielle Fröberg, Andreas Mårtensson 
The aim of this study was to describe temporal trends in the asymptomatic Plasmodium 
reservoir during the transition from high to low transmission in Zanzibar. Healthy individuals 
participating in cross-sectional surveys conducted in 2005, 2009, 2011 and 2013 were 
screened for asymptomatic malaria by cytb-qPCR. Infections were characterised with regards 
to Plasmodium species, geographic- and age distribution, qPCR-determined parasite 
densities, complexity and diversity of infection, and temporal trends in P. falciparum SNPs 
associated with amodiaquine resistance. See manuscript for detailed description of the 
statistical analyses. 
The main findings from this study include: 
 PCR-determined parasite prevalence declined from 21.1% (CI95%17.4-24.9) to 2.3% 
(CI95%1.7-2.9) from 2005-2013. As the prevalence of malaria declined, the 
proportion of subpatent infections increased (64.3%-91.2%). 
 P. falciparum remained the predominant species (78.5-100% of infections) followed 
by P. malariae (12.2-43.2%). No cases of P. ovale or P. vivax were identified. 
 The prevalence of asymptomatic malaria was higher in Micheweni than in North A 
for all years, although the difference was not significant in 2013. 
 In 2005 children aged 5-15 were most likely to have malaria (OR 3.8; CI95% 1.9-
7.4), whereas in 2011 and 2013 the burden was highest in young adults aged 15-25 
(OR 3.4; CI95% 1.3-8.8 and OR 3.7; CI95% 1.8-7.5, respectively). 
 The majority of asymptomatic infections had parasite densities lower than 10 
parasites/µL. Densities ranged from <1-28918 parasites/µL in P. falciparum 
monoinfections and 1-8 parasites/µL in P. malariae monoinfections. The median 
parasite density was significantly higher in 2005 than in the subsequent years 
(p<0.01). 
 There was a significant decrease in the MOI from 2.8 in 2005 to 1.7 in 2009 (p=0.01). 
Heterozygosity in the analysed loci was high. FST analysis did not detect any changes 
in the population of parasites from one year to another. 
 A significant decrease occurred in the asymptomatic samples in the pfcrt 76T allele 
frequency between 2005 and 2013 (99.2-64.7%, p<0.001) and in the pfmdr1 86Y 
allele frequency between 2009 and 2013 (89.4%-66.7%, p=0.03) (Figure 8). 
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 The pfmdr1 YYY and YYD haplotypes were significantly more frequent in the 
asymptomatic samples (p<0.001), whereas the pfmdr1 NFD was more frequent in the 
symptomatic samples (p<0.001) in 2013.  
 
 
 
 
 
 
 
 
 
Figure 8: Molecular genotyping of SNPs in P. falciparum infections. Clustered, stacked 
bar chart showing the frequency of polymorphisms associated with amodiaquine resistance. 
Error bars represent 95% confidence intervals of the proportion of isolates containing 
resistance alleles (either alone or in mixed infections). 
There is a declining, albeit persistent, reservoir of parasites present at low-densities in 
asymptomatic individuals in Zanzibar. As malaria prevalence declines, the epidemiology 
shifts resulting in temporal and spatial heterogeneity of malaria with concentration in 
particular localities and demographic groups. The majority of infections being subpatent 
shows the importance of implementing sensitive molecular methods for elimination efforts in 
Zanzibar. The decline in the prevalence of SNPs associated with amodiaquine resistance is 
similar and equally as intriguing as the results observed in Study I. The higher prevalence of 
SNPs in asymptomatic than symptomatic infections suggests that asymptomatic infections 
could be an important reservoir for resistance genes that confer a fitness disadvantage relative 
to wild type alleles [250]. However, little is known regarding the association between fitness 
and virulence, and the association is most likely dependent on a complex interplay between 
parasite fitness, host immunity, transmission intensity and drug pressure. 
Some limitations of this study include: 
 The cross-sectional design limits the understanding of the history, progression and 
dynamics of the infections. 
 The lack of reliable information on fever, treatment histories and gametocyte carriage 
provides little insight of the contribution of these infections to malaria transmission. 
 Clinical trials are required to assess the true efficacy of ASAQ in Zanzibar.  
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6.5 STUDY V 
Field deployment of loop-mediated isothermal amplification (LAMP) for centralised 
mass-screening of asymptomatic malaria in Zanzibar, a pre-elimination setting 
Ulrika Morris, Mwinyi Khamis, Berit Aydin-Schmidt, Ali Abass, Mwinyi I. Msellem, Majida 
Hassan Nassor, Iveth J. González, Andreas Mårtensson, Abdullah S. Ali, Anders Björkman, 
Jackie Cook 
The aim of this study was to report results from the hitherto largest implementation of LAMP 
(N=3983) in the field, for scaled up, centralised mass-screening of asymptomatic malaria. 
Samples were collected in 60 villages in ten districts throughout Zanzibar. All individuals 
present and willing to participate in randomly selected households were screened for malaria 
by RDT. Blood samples for LAMP were collected in every other household. LAMP was 
conducted in two centralised laboratories in Zanzibar, by trained technicians with limited or 
no previous experience of molecular methods. The LAMP assay was performed with 
Loopamp
TM
 MALARIA Pan/Pf Detection Kit (Eiken Chemical Company, Japan). Samples 
positive for Pan-LAMP were retested using Pf-LAMP specific kits. McNemar’s test was used 
to compare RDT and Pan-LAMP results. 
The main findings from this study include: 
 This is the largest hitherto reported implementation of LAMP for detection of 
asymptomatic malaria in a field setting. 
 The LAMP testing was centralised in order to scale up the breadth of sampling, 
meaning samples could be collected from all over the islands with fewer resources 
with a 24 hour time-to-result. 
 Sample collection was conducted during 19 days with an average of 220 samples 
processed per day in the two laboratories combined. The participation rate was high 
(96.9%) among subjects present at the time of the survey (Figure 9). 
 Pan-LAMP detected 3.4 (CI95% 2.2-5.2) times more Plasmodium positive samples 
than RDT (p<0.001). Out of the Pan-LAMP, samples 64.6% (42/65) were also 
positive by Pf-LAMP. 
 Repeatability of LAMP after freezing of diluted DNA was low (63.7%), suggesting 
that DNA extracted by simple methods such as the boil and spin may not be suitable 
for long term storage and should be amplified by LAMP within a short period of time. 
 During the study DNA contamination of LAMP arose in the central laboratory in 
Pemba. The contamination was resolved by repetitive decontamination of all 
equipment and reagents with 5% hypochlorite over 3 days, and moving away from 
the epicentre of the contamination to a laboratory space available in another building. 
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Figure 9: Flow chart of study. 
LAMP is a useful and sensitive tool for detection of low-density asymptomatic malaria 
infections in field settings. The potential risk of contamination with LAMP is high due to the 
high efficiency of the reaction, although the risk is reduced when using a closed system. 
Contamination issues have also been experienced in other research settings, but are not well 
reported; a higher throughput, affordable closed system would be ideal to avoid 
contamination issues. 
Some limitations of this study include: 
 A recent study in Zanzibar showed a larger presence of species other than P. 
falciparum than previously reported [216]. A LAMP pilot conducted in Zanzibar in 
2013 found that several P. falciparum infections positive in Pan-LAMP were missed 
by Pf-LAMP [88]. Although LAMP is a sensitive tool for detection of low-density 
infections, it does not provide a very detailed and/or accurate description of the 
Plasmodium species composition. 
 DNA extracted from whole blood by the boil and spin method is most likely not 
suitable for PCR, due to contamination with inhibitors of Taq polymerase such as 
haemoglobin [36]. LAMP can also be used on filter paper samples [83] which may be 
a preferable matrix for sample collection. Biological material from LAMP positive 
samples could then be stored and re-extracted for more detailed analysis of, for 
example, Plasmodium species, parasite density, and molecular markers of drug 
resistance by PCR. 
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6.6 ADDITIONAL RESULTS 
6.6.1 Summary of genotyping data 
Figure 10 shows a summary of all genotyping data presented in Study I and Study IV. The 
initial idea in Study IV was to compare all the available data, but due to the differences in 
study design between the clinical and cross-sectional surveys (e.g. year and age groups) we 
opted to only include the comparison between the 2013 asymptomatic and symptomatic 
samples in the manuscript. I hereby present the additional comparisons which are not 
presented in the manuscripts, bearing in mind the limitations regarding the differences in 
study design. SNP frequencies were defined, as in Study IV, as the proportion of isolates 
containing alleles associated with antimalarial drug resistance (including mixed infections), 
shown as the combined proportion of the black and striped stacked bars in Figure 10. SNP 
frequencies were compared by Fisher’s exact test. 
 
 
Figure 10: Molecular genotyping of SNPs in asymptomatic and symptomatic P. 
falciparum infections. Clustered, stacked bar chart showing the frequency of polymorphisms 
associated with amodiaquine resistance. Solid and spotted bars represent asymptomatic and 
symptomatic infections, respectively. Error bars represent 95% confidence intervals of the 
proportion of isolates containing resistance alleles (either alone or in mixed infections). 
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When comparing the baseline data in 2005 (asymptomatic) and 2002-2003 (symptomatic), 
the only significant difference was a higher prevalence of pfmdr1 Y184 in the symptomatic 
samples (99%) compared to the asymptomatic samples (89%) (p<0.001). 
In Study I a significant decline in the prevalence of resistance markers was observed in 
symptomatic fever patients between 2002-2003 and 2010. As described in the limitations of 
Study I, these results were based on the assumption that mixed infections contained two P. 
falciparum strains each contributing one SNP allele. These reductions remain significant 
(p<0.001 for all SNPs) when the calculations are repeated with frequencies defined as the 
proportion of isolates containing alleles associated with antimalarial drug resistance 
(including mixed infections). However, when mixed infections were removed completely, the 
significance was lost in pfmdr1 1246Y (p=0.8). 
The addition of the symptomatic data from 2013 showed a continuation of the trends 
described in Study I. There was a significant further decrease in the prevalences between 
2010 and 2013 in pfcrt 76T (72-47%, p<0.001) and pfmdr1 86Y (58-42%, p=0.03). There 
was a decline in the prevalence of pfmdr1 Y184 and 1246Y but the difference was not 
significant (79-68% p=0.08 and 17.1-8.5% p=0.09, respectively). The overall decrease from 
the baseline in the symptomatic samples was stronger (p<0.001 for all SNPs) than in the 
asymptomatic samples, where a significant decrease was only described in pfcrt 76T 
(p<0.001) since baseline and in pfmdr1 86Y after 2009 (p=0.03) (Study IV). 
In Study IV the prevalence of SNPs in the asymptomatic and symptomatic samples in 2013 
were compared, finding a significantly higher prevalence of pfmdr1 86Y and 1246Y in the 
asymptomatic samples (p=0.03 and p<0.01, respectively). The combined prevalence of the 
asymptomatic samples collected in 2009 and 2011 (N=117) were compared with the 
symptomatic samples collected in 2010 (N=122). The frequencies of pfcrt 76T, pfmdr1 86Y 
and 1246Y were significantly higher in the asymptomatic samples when compared with the 
symptomatic samples (p=0.004, p<0.001 and p=0.01, respectively).  
In conclusion, it seems that the baseline prevalence was similar between the asymptomatic 
and symptomatic samples. There has been a decline in the prevalence of SNPs in both the 
asymptomatic and symptomatic samples over the period of eight or ten years but the decline 
seems to have been more pronounced in the symptomatic samples. Differences in the fitness 
cost/benefits associated with these SNPs may affect the rate of reversion of these SNPs to 
wild type, in the presence of wide scale use of ASAQ. As mentioned in the discussion of 
Study IV, the differences between the asymptomatic and symptomatic samples are likely to 
depend on a complex interplay between parasite fitness, host immunity, transmission 
intensity, and drug pressure, and require further investigations in order to be fully understood. 
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6.6.2 Screening for mutations in pfkelch13 
A subset (N=70) of the samples collected on RDTs in health facilities in 2013 in Zanzibar 
(Study IV) were screened for mutations in the kelch propeller domain. Out of the 70 samples, 
34 (49%) were positive in the nested PCR published by Ariey et al. (2014) [152]. The 850bp 
PCR product was sequenced by Sanger sequencing in the forward direction only. Two SNPs 
were identified in the sequencing data in the initial round of screening (A582D in one sample 
and Y630stop in one sample). These SNPs were not present after repeating the PCR and 
sequencing of these samples (unpublished data). 
Bearing in mind the small sample size, these results show little evidence of pfkelch13 
polymorphisms in samples collected in Zanzibar. These results are consistent with other 
studies [166-168] which have shown absence in sub-Saharan Africa of the putative 
artemisinin resistance mutations in the pfkelch13 gene which have been described in SE Asia 
[93, 152, 159]. 
Although a high fidelity polymerase was used, two potentially false SNPs were observed in 
the sequencing data. It is important to note that unique SNPs should be validated in order to 
minimize the risk of reporting false results. Both PCR and Sanger sequencing present a small 
but inherent risk of introducing single nucleotide errors. 
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7 CONCLUSIONS 
 
7.1 OVERALL CONCLUSION OF THE THESIS 
This thesis shows that highly sensitive molecular methods are required for enhanced malaria 
infection detection and surveillance of antimalarial drug resistance in malaria pre-elimination 
settings such as Zanzibar. The application of molecular methods may be of particular interest 
for malaria control/elimination programs, for monitoring progress towards malaria 
elimination and for optimal orientation of program activities. Furthermore, intriguing trends 
in SNPs associated with antimalarial drug resistance, during a decade of wide scale use of 
ASAQ as the first-line treatment of uncomplicated malaria, were observed in Zanzibar. These 
trends require further investigation both in vivo, with clinical trials, and in vitro with further 
molecular methods. 
 
7.2 SPECIFIC CONCLUSIONS 
Study I: 
 Seven years of wide scale use of ASAQ as first-line treatment for uncomplicated 
malaria did not select for SNPs associated with resistance to the ACT partner drug 
amodiaquine. On the contrary, this study presented a decreased prevalence of pfcrt 
76T, pfmdr1 86Y, Y184 and 1246Y. 
 These results indicate sustained efficacy of ASAQ as first-line treatment in Zanzibar. 
However, the results were unexpected and call for more elaborated studies to improve 
the understanding of this observation. 
Study II: 
 Out of the three methods evaluated for DNA extraction from RDTs, the Chelex-100 
method proved most sensitive in both RDT and filter paper samples. 
 RDTs collected under field conditions were found to be a valuable source of parasite 
DNA and could reliably preserve parasite DNA for the purpose of molecular 
epidemiological investigations. 
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Study III: 
 The cytb-qPCR assay performed equal to or better than four reference PCR methods 
for the detection of low-density malaria infections, in DNA extracted by the Chelex-
100 method from samples collected on filter paper.  
 The results indicate that the cytb-qPCR may represent an opportunity for improved 
molecular surveillance of low-density Plasmodium infections in malaria pre-
elimination settings. 
Study IV: 
 There is a declining, albeit persistent, reservoir of parasites present at low-densities in 
asymptomatic individuals in Zanzibar. 
 The study revealed important characteristics of the remaining parasite populations, 
including intriguing temporal trends in molecular markers associated with 
antimalarial drug resistance. 
 The results highlight the need for sensitive molecular methods for identifying and 
characterising the residual parasite reservoir in malaria pre-elimination settings. 
Study V:  
 LAMP was found to be a simple and sensitive molecular tool, with potential for use in 
active surveillance and mass-screening programmes for the detection of low-density 
asymptomatic malaria in pre-elimination settings. 
 LAMP protocols may need to be adapted for processing large numbers of samples; a 
higher throughput, affordable closed system would be the ideal solution to avoid 
DNA contamination. 
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8 PERSONAL REFLECTIONS AND FUTURE 
PERSPECTIVES 
 
This thesis provides an insight into the application of modern molecular methods in a pre-
elimination setting such as Zanzibar. We developed and/or evaluated highly sensitive tools 
for enhanced malaria infection detection (Study III and Study V) and surveillance of 
antimalarial drug resistance (Study II). We observed a decrease in molecular markers 
previously associated with amodiaquine resistance, both in symptomatic (Study I) and 
asymptomatic individuals (Study IV) in Zanzibar, despite wide scale use of ASAQ over the 
last decade. I believe these insights are valuable for other pre-elimination settings in sub-
Saharan Africa, showing the need for sensitive molecular methods for improved malaria 
surveillance and control. 
 
8.1 IS MALARIA ELIMINATION FEASIBLE IN ZANZIBAR? 
Effective implementation and high uptake of malaria control interventions, such as access to 
parasitology based diagnosis for all age groups (primarily by RDTs), availability of 
efficacious malaria treatment free of charge (ASAQ), and universal coverage of LLINs and 
IRS, has resulted in a rapid transition in Zanzibar from high malaria transmission to pre-
elimination during the last decade. These malaria control interventions do not however, 
address the changes in malaria epidemiology that occur in areas transitioning from malaria 
control to elimination [199], where both geographically and demographically heterogeneous 
transmission and higher proportions of asymptomatic and subpatent infections are typical 
characteristics [205]. These characteristics make finding and targeting remaining parasite 
populations increasingly more difficult, perhaps explaining why Zanzibar, after an initial 
rapid decline in parasite prevalence, appears to be in a steady state of persistent low-level 
malaria transmission [Bjorkman and Shakely et al., submitted]. Zanzibar will require new 
tools and strategies, including surveillance and response systems that are able to detect and 
eliminate residual reservoirs of symptomatic and asymptomatic infections, in order to 
maintain progress towards malaria elimination. Such systems will need more sensitive 
molecular tools such as nucleic acid amplification based methods for monitoring parasite 
prevalence, genotyping for surveillance of genetic markers of drug resistance, and methods 
such as serology for accurate estimations of malaria transmission [198]. 
The Zanzibar malaria elimination feasibility assessment concluded that malaria elimination is 
technically feasible but will be operationally complex, with financing being one of the most 
critical challenges. It was estimated that 2020 was the earliest that elimination could 
reasonably be achieved, although interventions would need to be sustained for several 
decades regardless whether the programme aimed for malaria control or elimination [227]. 
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Treatment of all malaria infections with antimalarials reduces malaria transmission, 
especially if combined with gametocytocidal primaquine. However, asymptomatic malaria in 
semi-immune populations poses a difficult hurdle in obtaining 100% treatment coverage. In 
areas like Zanzibar, where immunity still exists, malaria control interventions must be 
sustained through a transition period long enough for clinical immunity to wane. In settings 
where there is no or little clinical immunity to malaria, most people who get malaria also get 
sick and are therefore rapidly treated and elimination becomes more stable [4]. Achieving and 
sustaining malaria elimination will require adequate and consistent funding. In the 1970’s 
Zanzibar attained very low levels of malaria by IRS with DDT, only to result in explosive 
resurgence of malaria when partner funds decreased and IRS was stopped [220]. Today 90% 
of Zanzibar’s malaria funding relies on international donors; perhaps increases in domestic 
financing, endowment funds and earmarked taxes could provide a more secure financing base 
for ZAMEP [227].  
One of the largest threats to sustained malaria elimination is importation of malaria. The 
technical feasibility assessment suggested that elimination in Zanzibar will require prevention 
of malaria reintroduction either by reduction of malaria in mainland Tanzania or through 
border screening of travellers and/or high risk groups [227]. Mobile phone usage data and 
ferry traffic between Zanzibar and mainland Tanzania, together with mathematical modelling 
of importation and transmission rates, were used to evaluate malaria importation rates [247]. 
Local transmission in Zanzibar was estimated too low to sustain transmission in most places, 
whereas the malaria importation rate was estimated to be 1.6 incoming infections per 1000 
inhabitants per year. The study concluded that malaria infections in Zanzibar largely resulted 
from imported malaria, and that Zanzibar residents travelling to malaria endemic regions 
were likely to be the single, most important source, contributing 1-15 times more imported 
cases than infected visitors. Malaria prevalence in mainland Tanzania is 9.2% (in children 
under the age of 5) and ranges from 3.6% -10.2% in the coastal regions closest to Zanzibar 
[251]. There are a number of ferry and airline companies travelling to and from Zanzibar, 
with hundreds of individuals arriving and leaving Zanzibar on a daily basis, not to count the 
numerous private fishing boats that may not leave via the main ports. This makes border 
controls almost impossible to establish. Other options could be screening of high risk travel 
groups, providing free prophylactics to Zanzibar residents travelling to the endemic mainland, 
and using insecticides in aeroplanes and ferries to stop the importation of mosquitoes. 
Estimating malaria importation remains technically and operationally challenging [247], but 
more precise estimates of Zanzibar’s importation risks are urgently needed [227].  
Due to the perceived threat of malaria importation, the technical feasibility assessment also 
suggested that intervention coverage needs to remain high (LLIN coverage of 75% or above), 
even after malaria elimination is achieved [227]. Vectorial capacity is reduced whilst vector 
control interventions are maintained, but once vector control is relaxed malaria transmission 
may return to baseline, making resurgence highly probable following reintroduction of 
malaria [4]. Resistance to pyrethroids also pose a serious threat to the sustained efficacy of 
vector control in Zanzibar. Furthermore, the near extinction of An. gambiae s.s. (usually 
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attributed to the success of IRS and LLINs against this endophilic and anthropophilic species) 
has resulted in An. arabiensis now being the main species of mosquitoes in Zanzibar [223]. 
An. arabiensis is an efficient malaria vector that feeds indoors and outdoors, on human and 
non-human hosts, and is not optimally controlled by indoor interventions. Vector control in 
Zanzibar is likely to need other tools in addition to LLINs and IRS [223]. 
The 50 countries that successfully eliminated malaria during the Global Malaria Eradication 
Programme launched in 1955 had higher GDP than countries that did not succeed in 
elimination [4]. In the 34 WHO listed malaria eliminating countries the gross domestic 
product has increased by 3.5% per year between 2000 and 2010 [199]. It is clear that 
economic wealth and urbanisation leads to declining malaria. It is also probable that a decline 
in malaria leads to economic growth, which in return would help a country maintain 
elimination once it is achieved [4]. Importantly housing structure improvements associated 
with accumulating wealth, such as closing of eaves, ceiling installation, window screens and 
use of tin roofs can prevent or discourage mosquitoes from feeding on humans [4]. I believe 
economic growth will precede malaria elimination in Zanzibar, and that molecular methods 
will play an important role in elimination efforts. 
 
8.2 HOW WILL MOLECULAR METHODS ASSIST MALARIA ELIMINATION? 
An ideal surveillance system would involve highly sensitive diagnostic tests, frequent malaria 
incidence counts, defining of geographical and demographic risk groups, real-time data 
regarding drug resistant parasites and insecticide resistant mosquitoes, accurate monitoring of 
transmission intensity, and recording of climatic data regarding rainfall. Data collected by 
mobile phones and SMS messaging, or directly though shared databases, could allow rapid 
deployment of interventions limiting further transmission, and could also allow data sharing 
for optimally coordinating activities between areas [196]. 
In Study II we found Chelex-100 extraction to be the most sensitive method for DNA 
extraction from RDTs and filter paper, after which this method was used in the following 
studies. Chelex-100 extraction provides a higher yield of DNA, and is therefore better suited 
for extraction of samples containing low-density infections, but may not provide DNA of 
equal quality as column based extraction methods. The DNA-containing supernatant, 
obtained with Chelex-100 extraction from filter papers, is often yellowish in colour especially 
if more than one 3mm filter paper punch is used. This suggests contamination of the sample 
with remaining haemoglobin, which may be inhibitory in some PCRs. The rigorous boiling 
used in Chelex-100 extraction can enhance DNA degradation during sample processing 
[231], and Chelex-100 extracted DNA is thought to be more susceptible to degradation 
during sample freeze-thawing [252]. In Study III we developed a highly sensitive PCR 
method specifically designed for screening low-density samples collected on filter paper and 
extracted by Chelex-100. The PCR amplifies a small fragment of DNA, in order to reduce the 
impact of DNA degradation, and targets the high copy number cytb gene, in order to improve 
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the sensitivity of the method. This method was used in Study IV for screening for malaria in 
filter paper samples collected in cross-sectional surveys.  
It is important to note that PCR detection limits vary with extraction method [49, 253, 254], 
with PCR protocol [49, 255], and also between laboratories [205, 256, 257]. Parasite densities 
that are on the cusp of the detection limit can alternate between being PCR positive and 
negative, and reproducibility of results may be low [207, 216]. Increasing blood sample 
volume can increase PCR sensitivity [76], but may be difficult to implement with large scale 
collection of samples in the field. Cross-sectional surveys also only provide a snap shot in 
time and may underestimate true parasite prevalence [258]. Furthermore, all PCRs presented 
in these studies were conducted in a research laboratory at Karolinska Institutet. As discussed 
in Study V, PCR is not yet available in resource limited settings due to the need of expensive, 
specialised equipment, reagents and know-how [77]. The methods presented here may be 
useful for research purposes, but most likely not for point-of-care or mass screening in field 
settings. Some attempts have been made to make PCR more accessible in the field, such as 
the use of an “in house” mobile laboratory for DNA extraction and real-time PCR screening 
in Cambodia [259]. The mobile laboratory enabled screening of 5000 individuals in less than 
4 weeks (on average 240 samples per day), providing treatment of parasite carriers within 24-
48 hours after sampling. Lab-on-chip PCR diagnostics could also overcome some of the 
challenges of malaria diagnosis and surveillance in the field. This involves a disposable 
plastic chip with a desiccated hydrogel containing reagents required for Plasmodium specific 
PCR and a low-cost (~2000 US$), portable, real-time PCR machine for DNA amplification. 
No sample processing is needed with the lab-on-chip, and the study reported a detection limit 
of 2 parasites/µL blood. Chips could be manufactured to test multiple targets simultaneously 
such as different pathogens, different species and genetic markers [260]. 
In Study V we report results from the hitherto largest implementation of LAMP in a field 
setting, for centralised, mass-screening of asymptomatic malaria. LAMP has several 
advantages over PCR for field use, as it doesn’t require expensive equipment, has faster time-
to-result, and provides results that can be read by eye. We employed a field friendly kit, 
which we found to be highly sensitive and simple to use. LAMP could potentially be adopted 
by malaria elimination programs for more accurate estimation of parasite prevalence in cross-
sectional surveys, and for mass screening and treatment purposes. DNA contamination is 
however, a problem with nucleic acid amplification based methods that needs to be 
addressed. We suggest that a higher throughput (e.g. 96 well plate), affordable closed system 
may help reduce, but still will not eliminate, the risk of contamination. Logistical issues in 
Zanzibar such as the unreliable supply of power from the mainland also poses unique 
challenges for wide scale implementation [251]. Adopting the lab-on-chip format for LAMP, 
that permits diagnosis using a single-use, electricity-free device (e.g. battery driven or heated 
by an exothermic reaction), could offer a possible alternative [51]. 
In Study IV we characterise temporal trends in PCR-determined asymptomatic Plasmodium 
infections. We report that there is a declining, albeit persistent, reservoir of parasites present 
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at low densities. The results highlight the need for sensitive molecular methods for 
identifying residual parasite reservoirs more accurately. More accurate characterisation of the 
residual parasite reservoir can also provide important information for malaria control 
programmes, allowing for reorientation and targeting of control activities. PCR-based testing 
has revealed a higher proportion of P. malariae than previously observed in Zanzibar. We 
report P. falciparum as the predominant species, followed by P. malaria which was present 
in up to 43% of infections in 2009. Other studies in Zanzibar have shown that 40% of PCR-
detectable malaria infections contained non-falciparum species [216], including reports of P. 
ovale and P. vivax [216, 261]. Zanzibar introduced the use of combo RDTs, that detect all 
species of malaria, but non-falciparum infections tend to be of lower density and may require 
more sensitive tools for detection [199]. P. vivax and P. ovale are very rare in Zanzibar, but 
an increase in prevalence could pose a problem for elimination efforts [216]. As burdens of P. 
falciparum decrease, malaria eliminating countries may need new strategies to diagnose, treat 
and interrupt transmission of non-falciparum malaria [199]. P. vivax and P. ovale hypnozoites 
are hard to detect when dormant in the liver, and can result in relapses of malaria if not 
treated correctly. Areas where P. vivax and P. ovale infections are prevalent may for 
example, require MDA with primaquine to eliminate infections [219]. 
Parasite densities are likely to be correlated with transmission intensity, immunity, rates of re-
infections and multiplicity of clonal subtypes [206]. In Study IV we found that parasite 
densities declined after 2005, after which the majority of the PCR detected infections had 
parasite densities lower than 10 parasites/µL. We also reported a shift in age; in 2005 children 
aged 5-15 were most likely to have malaria whilst in 2011 and 2013 the burden was highest 
in young adults aged 15-25. Increasing age has been significantly associated with lower 
parasite densities, and Okell et al. (2012) found significantly higher proportion of subpatent 
infections in older children and adults when compared to young children. This is most likely 
explained by greater immunity in older individuals, likely due to cumulative exposure and 
more developed immune systems [205]. This argument does not however, hold in high 
transmission settings where parasite densities are greater and the effect of age is overcome by 
time since last infection [205]. In Study IV we also use microsatellites to estimate the MOI, 
and found that the MOI declined after 2005 but the genetic diversity remained high. 
Microsatellites and genetic barcoding can also be used for tracking of parasites to identify the 
geographic origin of P. falciparum strains. This may be especially interesting in tracking the 
spread of artemisinin resistance [262] and to distinguish local and imported malaria infections 
[199].  
In summary, logistical constraints such as high costs, need for know-how, and the risk of 
contamination may limit the implementation of molecular methods at a point-of-care level. 
However, on a programmatic level molecular tools can provide important insights into the 
characteristics of the remaining parasite population, and will in my opinion be very useful for 
evaluating malaria elimination efforts and for providing important data that can be used for 
reorientation of elimination strategies. Treating all malaria infections is a prerequisite for 
malaria elimination. We have shown that standard malaria diagnostic tools including 
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microscopy and RDT are not sensitive enough to detect low-density asymptomatic infections. 
The cost effectiveness of for example deploying LAMP for MSAT needs to be evaluated 
against MDA, which overcomes the need for sensitive diagnostic tools but may increase the 
risk of drug resistance. A combination of reactive case detection, based on index cases, and 
FSAT or targeted MDA could be viable options in areas of low transmission where risk 
factors of malaria are not well defined [201]. FSAT still requires the use of sensitive 
diagnostic tools and targeted MDA (employing different classes of antimalarials then those 
used for individual case management [190] combined with a transmission limiting treatment 
such as primaquine [199]) requires close surveillance of molecular markers of drug 
resistance. 
 
8.3 WHAT CAN WE CONCLUDE FROM THE DECLINING PREVALENCE OF 
DRUG RESISTANCE POLYMORPHISMS IN ZANZIBAR? 
We observed a decrease in molecular markers previously associated with amodiaquine 
tolerance/resistance, both in symptomatic (Study I) and asymptomatic individuals (Study IV) 
in Zanzibar, despite wide scale use of ASAQ over the last decade. The methodology 
evaluated in Study II was also implemented in Study IV for drug resistance surveillance using 
malaria positive RDTs passively collected at health facilities in North A and Micheweni 
districts in 2013. Allele frequencies in these symptomatic samples were compared with allele 
frequencies in asymptomatic samples collected during a cross-sectional survey conducted the 
same year. 
The decrease in molecular markers associated with amodiaquine tolerance/resistance, 
observed in Study I and IV, and the lack of the putative artemisinin resistance mutations in 
the pfkelch13 gene reported in the additional results, may support the sustained efficacy of 
ASAQ as first-line treatment in Zanzibar. However, this conclusion would have to be 
confirmed by in vivo efficacy trials as markers of drug resistance may not predict clinical 
outcomes [10]. Several hypotheses to explain these results were put forward, including the 
importation of wild type parasites from the mainland Tanzania, a selection by artesunate per 
se, and the impact of parasite fitness associated with these alleles. Understanding the potential 
contribution of these hypotheses would require further investigations employing for example, 
tracking of parasite strains using microsatellite data to understand whether or not the parasites 
are imported, ex vivo assessment of the parasite susceptibility to artemisinins and in vitro 
assessment of parasite fitness. In vivo efficacy trials are also useful for assessing increases in 
parasite tolerance, but this is difficult to conduct in Zanzibar due to the low malaria 
prevalence, which limits the recruitment of patients and also results in low reinfection rates 
during the follow-up period. ASAQ has shown to select pfcrt 76T and pfmdr1 86Y, Y184 and 
1246Y after treatment, but little has been reported regarding trends in transporter 
polymorphisms after prolonged use of ASAQ, and it would be interesting to see if other areas 
with ASAQ as first-line treatment observe similar trends as in Zanzibar. 
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ASAQ and AL have shown to select in opposite directions after treatment [116], but the 
selection pressure seems to be stronger with AL than ASAQ. In contrast to the lack of 
reported selection of SNPs after long term use of ASAQ, increases of pfcrt K76 and pfmdr1 
N86, 184F and D1246 have been reported in areas where AL has been used as first-line 
treatment [128, 263-265]. AL could be more prone to the selection of resistance, as resistance 
to the partner drug lumefantrine is associated with wild type alleles, and the spread of 
resistance is therefore not inhibited by fitness costs of mutations as is for amodiaquine. 
Furthermore, pfcrt K76, pfmdr1 N86 and D1246 have been associated with decreased 
susceptibility to artemisinins in vitro [146-149], and it could be that artemether and 
lumefantrine select in the same direction, whilst artesunate and amodiaquine select in 
opposite directions. This just goes to show the importance of monitoring trends in molecular 
markers of drug resistance, and also the importance of regular clinical trials to monitor the in 
vivo response, in order to preserve the efficacy of ACTs. 
Finally we found that the decline in molecular markers was more pronounced in symptomatic 
compared to asymptomatic infections (additional results), and that asymptomatic infections 
had a higher prevalence of SNPs (Study IV and additional results). However, small sample 
sizes, and the lack of data regarding fever and treatment histories and age of these individuals 
make it difficult to draw any conclusions from these results. Age related immunity, treatment 
history and district could be important confounding factors. Similar findings have however, 
been reported in Uganda and Benin, where the prevalence of wild-type genotypes were 
higher in symptomatic compared to asymptomatic infections. It has been suggested that 
asymptomatic infections represent an important reservoir for resistance genes that confer 
fitness disadvantage relative to wild-type alleles, and may therefore contribute to the 
epidemiology of drug resistant malaria [250]. We conclude that differences in the ability to 
carry and clear drug resistant parasites are likely to depend on a complex interplay between 
parasite fitness, host immunity, transmission intensity and drug pressure.  
Parasite isolates can differ in their ability to invade erythrocytes, and consequently in their 
multiplication rates and number of merozoites they produce. It is conceivable that less fit P. 
falciparum isolates, that harbour mutations associated with significant fitness costs, produce 
low-density infections that are less likely to be detected by microscopy and more likely to be 
asymptomatic [65]. At the same time, higher gametocyte densities have been associated with 
mutations in pfcrt, pfmdr1, dhfr and dhps increasing the transmission potential of drug 
resistant parasites [266]. Host immunity also seems to play an important role in selection of 
drug resistance. Antimalarial drug resistance generally arises in areas of low transmission 
where there is little immunity to malaria. In these areas most infections are symptomatic and 
therefore treated, providing a greater drug pressure than in areas of high transmission; the 
lack of immunity may also reduce clearance of drug resistant parasites enhancing 
transmission [95]. In Zanzibar the drug pressure remains low, since the majority of infections 
are asymptomatic due to residual immunity after a recent decline in transmission. The low 
drug pressure may contribute to the lack of selection of resistance markers over time. On the 
other hand, a study in Kenya showed that submicroscopic infections were more common in 
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individuals reporting the use of non-ACT-based antimalarials in the preceding two weeks 
compared with individuals not reporting use of antimalarials [267], and data regarding 
previous use of antimalarials in the asymptomatic and symptomatic individuals would, of 
course, have been very valuable information. Finally, differences in human genetics in 
asymptomatic and symptomatic infections could also be a variable explaining the differences 
in the prevalence of SNPs. Amodiaquine is metabolised to DEAQ mainly by cytochrome 
P450 2C8 (CYP2C8). CYP2C8 low metaboliser alleles are present at 3.6% in Zanzibar [268]. 
Interestingly, a study conducted in Zanzibar showed that carriers of the low activity 
CYP2C8*3 had increased frequency of infections harbouring pfmdr1 86Y and 1246Y after 
treatment with ASAQ, perhaps due to the longer half-life for AQ in these individuals [269].  
In conclusion, we report a decrease in molecular markers previously associated with 
amodiaquine tolerance/resistance, both in symptomatic and asymptomatic individuals in 
Zanzibar. These results may indicate sustained efficacy of ASAQ as first-line treatment in 
Zanzibar. However, this would have to be confirmed by in vivo efficacy trials, as markers of 
drug resistance may not predict clinical outcomes. Finally, the decline in molecular markers 
was more pronounced in symptomatic compared to asymptomatic infections, and 
asymptomatic infections had a higher prevalence of alleles associated with resistance. 
Understanding these intriguing observations require further investigation both in vivo, with 
clinical trials, and in vitro with further molecular methods. 
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8.4 FUTURE PERSPECTIVES 
We are planning to assess a high throughput version of LAMP developed by FIND in the 
upcoming cross-sectional survey that will be conducted in May-June 2015. ZAMEP are also 
in the process of registering single low-dose (0.25 mg/kg) primaquine to be given on the first 
day of ACT treatment, as per WHO recommendations. A two arm in vivo efficacy trial 
(ASAQ and ASAQ + primaquine) is planned to be conducted in Zanzibar in the near future. 
This will be logistically challenging, but important to carry out since the last efficacy trial 
was conducted in 2005. 
Other things to consider in Zanzibar may include: 
 Evaluation of MSAT with LAMP versus targeted MDA programmes. 
 Case-control study design, for identifying risk factors of malaria. 
 Routine monitoring of antimalarial drug resistance markers and insecticide resistance 
in mosquitoes. 
 Accurate monitoring of malaria transmission by serology. 
 Gaining a better understanding of the transmissibility of low-density infections. What 
proportion of submicroscopic infections harbour or produce gametocytes, and at what 
densities? What is the transmissibility of these infections assessed by membrane and 
skin feeding assays? 
 Assessing the risk of malaria importation. Cross-sectional surveys conducted on 
ferries arriving and leaving Zanzibar could be an interesting study to conduct. This 
could allow for collecting more accurate information than what can be obtained with 
mobile phone usage data on malaria parasite importation and travel history. 
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